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ABSTRACT 
Mycobacterium tuberculosis and Human Immuno-Deficiency Virus (HIV) have a high 
prevalence in South Africa. The development and spread of drug resistant 
tuberculosis is a serious problem which is exacerbated by tuberculosis (TB) co-
infection in HIV patients. Traditional medicinal plants like Annona muricata and 
Artemisia afra are used for respiratory ailments and antiviral therapies respectively. 
The aim of this study was to evaluate Annona muricata (ethanolic extract) and 
Artemisia afra (ethanolic and aqueous extracts) for inhibitory activities against M. 
tuberculosis and HIV. In vitro bioassays for anti-TB activity included: microplate 
alamar blue assay (MABA), flow cytometry and ρ-iodonitrotetrazolium chloride 
assays while anti-HIV activity was determined using an HIV-1 reverse transcriptase 
colorimetric ELISA kit and an HIV-1 integrase colorimetric immunoassay. Cytotoxicity 
of plant extracts were assessed by the MTT assay on Chang Liver and HepG2 cells. 
Potential synergistic effects were determined using the basis of Combination Index. 
Potential interactions of plant extracts with drug metabolic pathways were evaluated 
with the Glutathione-S-Transferase assay kit as well as the CYP3A4 assay kit. A. 
muricata ethanolic extract exhibited anti-TB activity with MIC 125 µg/mL. MABA was 
shown to be the most sensitive and effective method for the detection of anti-TB 
activity. Artemisia afra aqueous extract showed HIV-1 reverse transcriptase inhibition 
exhibiting ˃85% inhibition at 1 mg/mL while the ethanolic extracts of A. afra and A. 
muricata showed inhibition of HIV-1 integrase activity at ˃86.8% and ˃88.54% 
respectively at concentrations >0.5 - 4 mg/mL. The aqueous extract of A. afra 
displayed inhibition of HIV-1 integrase ˃52.16% at 0.5 mg/mL increasing to 72.89% 
at 4 mg/ml of the extract. A. muricata was cytotoxic at an IC50 of 30 µg/mL and 77 
µg/mL on Chang Liver and HepG2 cells respectively, whilst A. afra aqueous and 
ethanol extracts were not cytotoxic to both cell lines. The ethanolic extract of A. 
muricata showed both antagonistic and synergistic properties at various IC values, 
when used in conjunction with rifampicin. A. afra ethanolic extract interrupted GST 
activity while aqueous extracts of A. afra and A. muricata had a slight effect. All 
extracts interrupted CYP3A4 activity, however the ethanolic extracts of A. muricata 
and A. afra showed greater inhibition than the aqueous extract of A. afra. These 
extracts should be investigated further as they could be an important source of 
compounds for treatment of M. tuberculosis and HIV respectively.  
iii 
 
LIST OF FIGURES 
  Page 
Figure 1.1: Principle of Reverse Transcriptase Assay  ...........9 
Figure 3.1: Anti-TB activity of A. muricata using MABA. ..........36 
Figure 3.2: Percentage inhibition of M. tuberculosis determined using MABA for the five 
control drugs and for A. muricata.  .........37 
Figure 3.3: Anti-TB activity of A. muricata using INT assay. ..........37 
Figure 3.4: Percentage inhibition of M. tuberculosis determined using INT for the five 
control drugs and for A. muricata. .........38 
Figure 3.5: Flow cytometry data of the M. tuberculosis culture H37Rv ATCC 27294 
exposed to various concentrations of (A) ethambutol (B) Annona muricata 
versus the untreated growth control. ..........39 
Figure 3.6: Visual representation of colour change observed for five concentrations (in 
triplicate) of the aqueous extract of Artemisia afra. ..........41 
Figure 3.7: Percentage inhibition of HIV-1 reverse transcriptase obtained for various 
concentrations of ethanolic extract of A. muricata and aqueous and 
ethanolic extracts of Artemisia afra. Positive control [Nevirapine (Aspen) – 2 
mg/ml, 100% inhibition]. Data points represent the mean ± SD of three 
determinations, representative of three independent experiments ..........41 
Figure 3.8: Percentage inhibition of HIV-1 integrase obtained for various 
concentrations of ethanolic extract of A. muricata and aqueous and 
ethanolic extracts of Artemisia afra. Data points represent the mean ± SD 
of three determinations, representative of three independent experiments ..........42 
Figure 3.9: Percentage inhibition of HIV-1 integrase obtained for various 
concentrations of sodium azide (a known inhibitor of HIV-1 integrase). ..........43 
Figure 4.1: Cytotoxic effect of A. muricata ethanol extract on confluent Chang liver cells 
after 24 hours of exposure. ..........51 
Figure 4.2: Cytotoxic effect of Rifampicin on confluent Chang liver cells after 24 hours 
of exposure. ..........52 
iv 
 
Figure 4.3: Cytotoxic effect of A. muricata ethanol extract on confluent HEPG2 cells 
after 24 hours of exposure. 
..........52 
Figure 4.4: Cytotoxic effect of Rifampicin on confluent HEPG2 cells after 24 hours of 
exposure. 
..........53 
Figure 5.1: Percentage inhibition of GST activity of the extract and inhibitor free control 
compared to the test samples where the various plant extracts are present.  
...........63 
Figure 5.2: Percentage inhibition of cytochrome 3A4 due to the presence of various 
concentrations of the ethanolic extract of A. muricata and the ethanolic and 
aqueous extracts of A. afra. ...........64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
LIST OF TABLES 
  Page 
Table 1.1: Treatment guidelines of MDR-TB and XDR-TB (Dept. Of Health, S.A; 
Streicher et al., 2012) ...........4 
Table 2.1: Assay Conditions (Life Technologies, USA) 
...........29 
Table 2.2: Reconstitution of the CYP3A4 substrates (Life Technologies, USA) 
...........29 
Table 2.3: Master pre-mix preparation for the CYP3A4 isozyme (Life Technologies, 
USA) ..........30 
Table 2.4: Preparation of the substrate and NADP
+
 (Life Technologies, USA) 
..........30 
Table 2.5: Excitation and emission wavelengths for the various fluorescent standards 
(Life Technologies, USA). The red fluorescent standard was used for this 
specific experiment ..........31 
Table 3.1: Comparison of the assays used for detection of anti-tuberculosis activity 
..........40 
Table 4.1: Summary of the IC25, IC50 and IC70 values obtained for the ethanolic extract, 
A. muricata alone, rifampicin alone as well as the IC25, IC50 and IC70 values 
of each when used in combination for both the Chang liver and HEPG2 cell 
lines. Combination index also provided 
..........54 
 
 
 
 
 
 
 
 
vi 
 
LIST OF ABBREVIATIONS 
AIDS Acquired immune deficiency syndrome 
ADC Albumin-dextrose-catalase 
ATCC American Type Culture Collection 
ARV Antiretroviral 
Anti-DIG-POD Anti-digoxigenin-peroxidase 
ATP Adenosine Triphosphate 
Bsc Bachelor of science 
BaCl2 Barium Chloride 
CO2 Carbon dioxide 
CDC Centers for disease control 
CLSI Clinical Laboratory Standards Institute 
CD4 Cluster of differentiation 4 
CD8 Cluster of differentiation 8 
°C Degrees Celsius 
CI Combination Index 
C-terminus Carboxyl terminus 
C-3 Carbon 3 
CYP3A4 Cytochrome 3A4 
CDNB 1-Chloro-2,4-dinitrobenzene 
DMSO Dimethyl sulfoxide 
DOH Department of Health 
DOTS Directly observed treatment 
ddH2O Double distilled water 
DPBS Dulbecco’s Phosphate Bufferred Saline 
deCIPhR Dual enhancement of Cell Infection to Phenotype Resistance 
DNA Deoxyribonucleic acid 
dUTP Digoxigenin Uridine Triphosphate 
DS Donor Substrate 
EMB Ethambutol 
XDR-TB Extensively drug resistant TB 
EMEM Eagles Minimum Essential Medium 
ELISA Enzyme Linked Immunosorbent Assay 
FDA Fluoroscein diacetate 
FRET Fluorescent Resonance Energy Transfer 
FBS Foetal Bovine Serum 
g grams 
xg gravity 
Gag Group specific Antigen 
vii 
 
Gag-Pol Group specific Antigen Polypepdtide 
GST Glutathione-S-Transferase 
HAART Highly Active Antiretroviral Therapy 
HTS High-throughput screening 
h hours 
HIV Human immunodeficiency virus 
HRP Horse Radish Peroxidase 
HSD Honestly Significant Difference 
INH Isoniazid 
IC Inhibitory Concentration 
iFIGS Infection format of Fusion Induced Gene Stimulation 
Log Logarithmic 
MABA Microplate Alamar Blue Assay 
mg Milligram 
mL Millilitre 
mM Millimolar 
MIC Minimum inhibitory concentration 
min Minutes 
MDR-TB Multi-drug resistant TB 
Mono-THF Mono-Tetrahydrofuran 
MRP Multiple Resistance Protein 
MTT 4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
m Metres 
ng Nanograms 
nm Nano-meters 
nM Nanomolar 
ND Not Determined 
NEAA Non-essential Amino Acids 
NRTI Nucleoside Reverse Transcriptase Inhibitor 
NNRTI Non-nucleoside Reverse Transcriptase Inhibitor 
NARTI Nucleoside analogue Reverse Transcriptase Inhibitor 
NYU New York University 
N-terminus Amino terminus 
NAD
+ 
Nicotinamide adenine dinucleotide 
NADH Nicotinamide adenine dinucleotide (reduced form) 
NADPH Nicotinamide adenine dinucleotide phosphate (reduced form) 
NHLS National Health Laboratory Services 
N Normal 
NMMU Nelson Mandela Metropolitan University 
OFX Ofloxacin 
viii 
 
OA Oleanolic Acid 
INT p-Iodonitrotetrazolium chloride 
PE Port Elizabeth 
PZA Pyrazinamide 
P-gp P-glycoprotein 
PI Protease Inhibitor 
PAPS 3’-phosphoadenosine 5’-phosphosulfate 
pg Picogram 
R Rand 
RIF Rifampicin 
RT Reverse Transcriptase 
RFU Relative fluorescence units 
NaOH Sodium Hydroxide 
spp. Species 
SM Streptomycin 
-SH Sulfhydral 
sec Second 
SD Standard Deviation 
SRB Sulforhodamine B 
SULT Sulfotransferase 
TB Tuberculosis 
TS Target Substrate 
TMB 3,3', 5,5'-tetramethylbenzidine 
μL Microlitres 
μm Micrometres 
μM Micromolar 
UV Ultraviolet Light 
vol/vol Volume/volume 
w/v Weight/volume 
WHO World Health Organization 
 
 
 
 
 
 
 
1 
CHAPTER ONE 
 
LITERATURE REVIEW 
 
1.1 INTRODUCTION 
Mycobacterium tuberculosis and Human Immuno-Deficiency Virus (HIV) have a high 
prevalence in South Africa. Despite the fact that more than 40 years has been placed 
behind anti- tuberculosis (TB) chemotherapy, TB still remains one of the main 
infectious killers worldwide (Luo et al., 2011). There were 9.4 million new cases 
(including 1.1 million cases among people with HIV) and 1.7 million deaths from TB 
(including 380 000 people with HIV) in 2009 (WHO, 2010). HIV has been estimated to 
have infected 34 million people worldwide, where South Africa’s HIV epidemic remains 
the largest in the world, with an estimated 5.6 million HIV positive people as of 2009. 
This exceeds the number of people living with HIV in the entire Asian region 
(www.who.int/hiv/pub/progress_report2011/en/index.html). 
 
The use or mis-use of anti-tuberculosis drugs has led to an increasing prevalence of 
multi-drug resistant (MDR) and extreme drug resistant (XDR) M. tuberculosis strains, 
emphasising the need for novel and improved drugs for treatment of TB. There is a 
renewed and increasing interest in plant medicine as these are seen as potential 
sources of new compounds for drug development (Luo et al., 2011).  
 
Many plant species are used in traditional South African medicine to alleviate 
symptoms of TB and several lead compounds have been reported for further research 
following in vitro antimycobacterial activity evaluation. However, more research is 
needed on the assessment of anti-mycobacterial efficacy of plants against M. 
tuberculosis both in vitro and in vivo (McGaw et al., 2008). Current antiretroviral drugs 
are vitally important to improve the quality and prolong the life of HIV/AIDS patients. 
However, these drugs have many disadvantages including resistance, toxicity, limited 
availability, high cost and lack of any curative effect. Thus, it is important to search for 
improved antiretroviral agents which can be added to or replace the current drugs in 
the anti-HIV spectrum (Klos et al., 2009).  
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In this study, two plants, namely Annona muricata and Artemisia afra were 
investigated for inhibitory activity against M. tuberculosis and HIV. A. afra is one of the 
most popular and commonly used herbal medicines in Southern Africa. However, only 
limited research has been conducted on this species which is rich in terpenes. It has 
been reported that A. afra exhibits some antiviral activity or immune boosting 
properties (Liu et al., 2009). There are few reports on A. muricata, which indicate that 
all parts of the tree have been used to treat multiple illnesses (Boyom et al., 2011). 
The leaves are especially used as an antispasmodic, sedative, also for respiratory 
tract conditions (coughs, grippe, asthma, catarrh and asthenia) (Asprey and Thornton, 
1955). 
 
Due to a variety of compounds that could possibly be present in A. afra and A. 
muricata, it is important to understand what major compounds are present in these 
plants and the potential effects they could have on the existing treatment drug-
metabolizing pathways. Many HIV/AIDS patients use traditional plant remedies in 
conjunction with drug therapies provided by clinics and hospitals which may result in 
drug-herbal pharmacokinetic and pharmacodynamic interactions (Brown et al., 2008; 
Balayssac et al., 2005; Patel et al., 2011). Some pharmacokinetic interactions include 
changes in the absorption of the co-administered drug, thus affecting its bioavailability, 
its therapeutic effectiveness or by producing drastic side effects (Brown et al., 2008; 
Balayssac et al., 2005). 
 
1.2 MYCOBACTERIUM TUBERCULOSIS 
1.2.1 Epidemiology and Pathogenesis 
Tuberculosis in humans is caused by M. tuberculosis, which is a non-motile, rod-
shaped bacterium (2 - 4 µm in length and 0.2 - 0.5 µm in width), with non-pathogenic 
forms being found as part of the normal microflora of humans. M. tuberculosis has 
been classified as a facultative intracellular parasite, with a generation time of between 
12 - 18 hours (Black, 2011). Tuberculosis can be diagnosed, by clinical evaluation 
(fever, night sweats, loss of weight and coughing), the tuberculin skin test, chest X-
rays and microbiological analysis (Dev Pandey et al., 2008 and Van Helden et al., 
2006). 
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Tuberculosis is acquired by the inhalation of respiratory secretions containing tubercle 
bacilli. M. tuberculosis multiplies slowly within the host’s macrophages stimulating a 
host immune response, resulting in large amounts of fluid being released into the lung 
tissue producing pneumonia-like symptoms. In some instances, M. tuberculosis can 
enter the lymphatic and circulatory systems, which can lead to the perforation of blood 
vessels resulting in the production of bloody sputa, one of the most important and 
defining symptoms of tuberculosis. Extrapulmonary tuberculosis can be found within 
the urogenital tract, meninges, lymphatic system, spleen and bones, and the spinal 
cord (Bauman, 2011). 
 
South Africa is ranked third in the world with tuberculosis infections and is one of the 
22 high burden countries that contribute approximately 80% to the total global TB 
cases. The development and spread of drug resistant tuberculosis is a serious 
problem for South Africa, and is responsible for the largest number of multi-drug 
resistant TB (MDR-TB) cases in the world and the largest reported outbreak of 
extensively drug resistant TB (XDR-TB) (WHO, 2010). The total number of MDR- and 
XDR-TB cases recorded for the different provinces of South Africa, during 2004 - 
2011, were Limpopo (MDR-TB: 943 and XDR-TB: 27), Western (MDR-TB: 11946 and 
XDR-TB: 386) and Eastern Cape (MDR-TB: 9154 and XDR-TB: 962); KwaZulu-Natal 
(MDR-TB: 11393 and XDR-TB: 1499) and Gauteng (MDR-TB: 6994 and XDR-TB: 
237) (Koornof et al., 2011 and www.doh.gov.za/docs/policy/2011/policy_TB.pdf). 
 
1.2.2 Treatment and Drug Resistant Tuberculosis (TB) 
Drug-resistant tuberculosis is defined as the resistance of M. tuberculosis to at least 
one first-line anti-tuberculosis drug (CDC, 2010). Likewise extensively drug resistant 
TB (XDR-TB) is defined as resistance to at least rifampicin and isoniazid (MDR-TB), in 
addition to any fluoroquinolone, and at least one of the three following injectable drugs 
capreomycin, kanamycin, and amikacin used for MDR-TB treatment (Streicher et al., 
2012). The treatment of active tuberculosis involves the use of one or more drugs, 
administered for a minimum of six months under strict clinical management (Bapela et 
al., 2006; Matsumoto et al., 2006).  
 
The standard first-line antibiotics used include isoniazid (INH), rifampicin (RIF), 
ethambutol (EMB), streptomycin (SM) and pyrazinamide (PZA) (Bapela et al., 2006; 
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Johnson et al., 2006). Isoniazid is a very efficient mycobactericidal drug, and is 
capable of significantly reducing the transmission of tuberculosis, while rifampicin, 
plays an important role in the prevention of TB re-activation, as it is capable of killing 
off metabolically active M. tuberculosis cells (Suresh et al., 2006 and Sharma and 
Mohan, 2004). Resistance to either isoniazid or rifampicin can be managed by using 
other first-line antibiotics; but with the emergence of multi-drug resistance, treatment 
protocols have been further complicated as second-line drugs are now required.  
 
Table 1.1:  Treatment guidelines of MDR-TB and XDR-TB (Dept. of Health, S.A; Streicher et al., 2012). 
 
Unfortunately, second-line antibiotics have many limitations making them unsuitable 
for short treatment programmes. MDR-resistant patients require prolonged treatments 
with antimicrobial drugs that are less effective, more expensive, slightly more toxic, 
and have the possibility of leading to undesirable drug interactions, as some 
antiretrovirals and anti-TB drugs cannot be used simultaneously (Matsumoto et al., 
2006 and Sharma and Mohan, 2004).  
 
However, for the first time in 40 years, a large number of pharmaceutical companies 
have focussed on drug discovery to develop new chemical entities using either target 
based or phenotypic screens (Villemagne et al., 2012). There are at least ten 
compounds in clinical trials, four of which are existing drugs that are being re-
developed or re-purposed for TB treatment and then there are six new compounds 
that are being developed for TB treatment. It is unfortunate that majority of these drugs 
MDR-TB XDR-TB 
Intensive Phase Continuation Phase Intensive Phase Continuation Phase 
Kanamycin (IM)  Capreomycin (IM)  
Ethionamide Ethionamide Ethionamide Ethioamide 
Pyrazinamide Pyrazinamide   
  ρ-aminosalicyclc acid ρ-aminosalicyclic acid 
Ofloxacin Ofloxacin Moxifloxacin Moxifloxacin 
Terizidone or cycloserine Terizidone or cycloserine Terizidone or cycloserine Terizidone or cycloserine 
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are still present in preclinical testing (Villemagne et al., 2012 and Zhenkun, 2010). 
Currently there are three drugs which have great promise for the release for public use 
as they are proving to be very effective in phase 3 trials, namely Bedaquiline, 
Delaminid and PaMZ. Bedaquiline and Delaminid, have shown to be effective at 
shortening the duration of treatment against MDR-TB where PaMZ, a combination 
therapy using a novel drug moxifloxacin and pyrazinamide, has shown effectiveness 
against TB, with 99% of TB bacteria killed within two weeks as well as some forms of 
drug-resistant TB (http://blogs.sun.ac.za/news/2012/07/25/new-tb-drugs-bring-hope-in-
fight-against-tb/). 
 
1.3 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 
1.3.1 Epidemiology and Pathogenesis 
Human immunodeficiency virus (HIV) is a lentivirus that causes acquired 
immunodeficiency syndrome (AIDS), a condition in humans resulting in the 
progressive failure of the immune system. Infection with HIV occurs by the transfer of 
blood, semen, vaginal fluid, pre-ejaculate or breast milk. Within these body fluids, HIV 
is present as both free virus particles and virus within infected immune cells. This 
infection is regarded as a communicable disease where sexual transmission is the 
most common mode of HIV transmission (UNAIDS Report on the Global Aids 
Epidemic, 2010). The rate of new infection worldwide is estimated at 2.7 million per 
year (UNAIDS, 2010). 
 
HIV infects vital cells in the human immune system such as helper T cells (specifically 
CD4+ T cells), macrophages and dendritic cells. When CD4+ T cell numbers decline 
below a critical level, cell mediated immunity is lost and the body becomes 
progressively more susceptible to opportunistic infections (Cunningham et al., 2010). 
 
1.3.2 Treatment Regimes 
Treatment for HIV ranges from the use of nucleoside reverse transcriptase inhibitors 
(NRTI’s), highly active antiretroviral therapy or otherwise known as HAART, which 
introduced protease inhibitors and then the non-nucleoside reverse transcriptase 
inhibitors (NNRTI’s) (Karim and Karim, 2010). HAART provides combinations 
consisting of at least three drugs belonging to at least two types of antiretroviral 
agents. Typically, these are two nucleoside analogue reverse transcriptase inhibitors 
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(NARTIs or NRTIs) and either a protease inhibitor or a non-nucleoside reverse 
transcriptase inhibitor (NNRTI) (NYU Medical Centre, 2009). The NRTI’s, such as 
Zidovudine, Lamivudine and Emtricitabine, are analogues of the nucleosides required 
for DNA synthesis. They differ in that they lack the 3’-hydroxyl group of the ribose ring 
and when they become phosphorylated they can be incorporated into the growing 
DNA strand, however once this occurs, DNA synthesis halts due to the absence of the 
3’ hydroxyl group (Karim and Karim, 2010).   
 
NNRTI’s, such as Nevirapine and Efavirenz, do not undergo chemical modification in 
order to become active and the different members in this group have diverse chemical 
structures. They are relatively small and act by binding non-competitively to the active 
receptor site of the reverse transcriptase enzyme. This causes a change in the three 
dimensional structure of the enzyme and thus impairment of the polymerase activity 
(Karim and Karim, 2010). 
 
Protease inhibitors (PI’s), such as Ritonavir, Indinavir and Amprenavir, are also 
structurally diverse molecules which require no chemical modification in order to 
become active. They are metabolized in the liver and the gut by the P450 enzyme 
system, which results in multiple interactions with other hepatically metabolized drugs 
(Karim and Karim, 2010). These drugs target the HIV encoded protease enzyme, 
which is responsible for cleaving the HIV protein precursor transcript into its subunits 
prior to the virion assembly and the export of the new virus from the infected cell. They 
bind to the central, active cleavage site of the HIV protease heterodimer (Karim and 
Karim, 2010).  
 
There is currently no available vaccine or cure for HIV or AIDS, however a number of 
trials have been conducted using two different vaccines in sequence or in 
combination, now being referred to as the prime boost strategy, including many trials 
combining a DNA plasmid with a viral vector, based on either poxvirus or adenovirus, 
combining DNA plasmid with protein, or combining a protein vaccine with a viral vector 
(Fast and Kaleebu, 2010). In general, the prime boost trials have shown a synergistic 
effect of the two components. RV144, the most recent efficacy trial in Thailand showed 
30% reduced incidence of infection in the group that received a prime boost vaccine 
(Veronin and Phogat, 2010 and Fast and Kaleebu, 2010). A vaginal gel containing 
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tenofovir, a reverse transcriptase inhibitor, was shown to reduce HIV infection rates by 
39% in a trial conducted in South Africa (Karim and Karim, 2010). 
 
1.4 IN VITRO BIOASSAYS FOR EVALUATION OF PLANT EXTRACTS 
 
1.4.1 Inhibition of M. tuberculosis  
1.4.1.1 Microplate Alamar Blue Assay (MABA) 
Microbroth dilution susceptibility tests in 96-well microplates offers the advantages of 
small sample requirements, low cost and high-throughput including the potential for 
automation (Pauli et al., 2005). Microplate Alamar Blue assay (MABA), a colorimetric 
drug-susceptibility testing method uses an oxidation/reduction indicator dye, alamar 
blue that changes colour from blue to pink to indicate bacterial growth and can be read 
visually without the need for instrumentation (Collins and Franzblau, 1997). The 
reduced form of the dye can also be quantitated colorimetrically by measuring 
absorbance at 570 nm (and subtracting absorbance at 600 nm; the peak for the 
oxidised form), or fluorimetrically by exciting at 530 nm and detecting emission at 590 
nm (Collins and Franzblau, 1997).  
 
MABA has been used previously for drug-susceptibility testing of M. tuberculosis 
against antituberculosis drugs and has also been used for screening other 
antimicrobial agents against M. avium and M. tuberculosis (Collins and Franzblau, 
1997; Franzblau et al., 1998; Bastian et al., 2001). Multiple drug, extract or compound 
concentrations can be tested using MABA (Gautam et al., 2007; Ananthan et al., 
2009; Lougheed et al., 2009; Green et al., 2010). 
 
1.4.1.2 p-Iodonitrotetrazolium chloride (INT) Assay 
This assay is a microplate assay, which is very similar to that of MABA, however it 
determines the MIC of plant extracts using p-Iodonitrotetrazolium chloride (INT) dye. 
The tetrazolium dye (INT) acts as an electron acceptor and is reduced to a coloured 
product by biologically active organisms. Viable bacteria reduce the yellow dye to a 
purple/pink colour and the MIC is defined as the lowest sample concentration that 
prevents change in colour and exhibits complete inhibition of bacterial growth. When 
larger volume tube assays were used on plant extract testing, precipitation of insoluble 
components and the green colour of the extracts made it difficult, if not impossible to 
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determine the MIC which explains why it is not often used for screening plant extracts 
(Eloff, 1998).  
 
This assay has been used for detection of antimicrobial activity using control bacteria 
such as Bacillus subtilis, Staphylococcus aureus, Streptococcus spp, Escherichia coli 
and Pseudomonas aeruginosa (Eloff, 1998; Smith and McFeters, 1997; Kuete et al., 
2008) but not for M. tuberculosis. 
 
1.4.1.3 Flow Cytometry 
Flow cytometry has been used for the detection of M. tuberculosis that are resistant or 
susceptible to antimicrobial agents (Kirk et al., 1998; DeCoster et al., 2005; Pina-Vaz 
et al., 2005; Fredricks et al., 2006). The main advantage of flow cytometry is the 
shorter time required to obtain a result (Fredricks et al., 2006; Kirk et al., 1998). 
Fluorescent dyes such as fluorescein diacetate (FDA) (Norden et al., 1995; Kirk et al., 
1998; Reis et al., 2004) or SYTO16 (Pina-Vaz et al., 2005; Govender et al., 2010) 
have been used for detection of resistance in M. tuberculosis isolates. 
 
The method is based on the ability of mycobacteria to hydrolyse fluorescein diacetate 
to free fluorescein via non-specific cellular esterases. Accumulation of fluorescein in 
metabolically active mycobacterial cells can then be easily detected by using a flow 
cytometer. By contrast, mycobacteria that are killed or inhibited by antimycobacterial 
agents hydrolyse significantly less FDA and therefore have reduced levels of 
fluorescence (Kirk et al., 1998). Safety is a primary concern when working with M. 
tuberculosis and has been improved by procedures such as exposure to 10% 
formaldehyde for one hour that kills the mycobacteria prior to flow cytometry testing 
without compromising their staining characteristics (Norden et al., 1995; Moore et al., 
1999). 
 
Flow cytometry with the fluorescent nucleic acid stain SYTO16 can also be applied to 
screening of anti-tuberculosis agents against M. tuberculosis (Pina-Vaz et al., 2005). 
M. tuberculosis cells are grown in the absence or presence of antimycobacterial drugs 
and heat-killed, stained with SYTO16 and then analysed by flow cytometry. An isolate 
was considered sensitive whenever the number of fluorescent particles in the drug-
containing medium was reduced in comparison to the untreated growth control (Pina-
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Vaz et al., 2005). Although the use of heat killed cells stained with SYTO16 ensures 
biosafety, the small size of M. tuberculosis and their tendency to aggregate makes 
analysis fairly challenging (Fredricks et al., 2006; Akselband et al., 2005; Pina-Vaz et 
al., 2005; Kirk et al., 1998 and Ryan et al., 1995). However, a disadvantage 
associated with the use of this stain, is the relatively high cost (R6 000 for 250 µL), 
which could be problematic if large numbers of anti-tuberculosis drugs need to be 
screened (Govender et al., 2010). 
 
1.4.2 Screening for Activity against HIV 
1.4.2.1 Reverse transcriptase inhibition 
Bioassays to determine anti-HIV activity involve screening for presence of HIV-specific 
enzyme inhibitors. The Reverse Transcriptase (RT) assay is a colorimetric enzyme 
immunoassay for the quantitative determination of retroviral reverse trancriptase 
activity by incorporation of digoxigenin and biotin labelled dUTP into DNA 
(www.cssportal.roche.com/LFR_PublicDocs/ras/11468120910_en_13.pdf). 
The detection and quantification of the synthesized DNA as a parameter for RT activity 
follows a sandwich ELISA protocol, where the biotin labelled DNA binds to the surface 
of streptavidin coated microplate components. An antibody to dig-oxigenin, conjugated 
to peroxidase (anti-DIG-POD), is then added and binds to the dig-oxigenin labelled 
nucleotides. A peroxidase substrate is then added so that the peroxidase enzyme can 
catalyze the cleavage of the substrate to produce a coloured reaction product. The 
absorbance of the samples is determined using a microplate reader and is directly 
correlated to the level of RT activity in the sample 
(www.cssportal.roche.com/LFR_PublicDocs/ras/11468120910_en_13.pdf). 
 
 
Figure 1.1: Principle of Reverse Transcriptase Assay 
(www.cssportal.roche.com/LFR_PublicDocs/ras/11468120910_en_13.pdf). 
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1.4.2.2 HIV-integrase inhibition 
The HIV-1 integrase assay was developed for the screening of HIV-1 integrase 
inhibitors using a colorimetric enzyme immunoassay. This assay can be used to 
quantitatively measure the inhibition of HIV-1 strand transfer activity due to the 
presence of interacting agents (www.xpressbio.com/ebi/pdf/EZ-
1700hiv_integrase_wildtype_kit%20v%203.0_pi_061411.pdf). Integrase catalyses two 
sequential, spatially distinct and metal-dependant reactions, namely 3’-end processing 
and strand transfer. Although inhibitors of both steps have been identified, only agents 
that inhibit the strand transfer reaction have been shown to be biologically active in 
cell based assays and in vivo (www.xpressbio.com/ebi/pdf/EZ-
1700hiv_integrase_wildtype_kit%20v%203.0_pi_061411.pdf).  
 
This assay functions by detecting the absence of strand transfer and thus if an 
inhibitor is not present, the HIV-1 integrase incorporates the target DNA into donor 
DNA and the products of the reaction can be determined through a colorimetric 
reaction. If a strand transfer inhibitor is present, this will reduce product formation and 
this inhibitory activity of the test agent can then be determined quantitatively 
(www.xpressbio.com/ebi/pdf/EZ-
1700hiv_integrase_wildtype_kit%20v%203.0_pi_061411.pdf). Drugs which are 
inhibitory to integrase would therefore be valuable in antiviral therapy (Craigie, 2001). 
 
1.4.2.3 HIV-1 protease inhibition 
The HIV-1 protease assay was developed for the screening of HIV-1 protease 
inhibitors. This fluorescence resonance energy transfer (FRET) based assay could 
also be used for quantification of HIV-1 protease. The Human immunodeficiency virus 
type 1 (HIV-1) precursor poly-protein is generated during the virion maturation 
process. HIV-1 protease is responsible for cleaving up to 12 sites in the group specific 
antigen (Gag) and Gag-Pol precursor polypeptides (Klos et al., 2009). The order of 
cleavage and the extent of precursor processing appear to be critical steps in the 
generation of fully infectious, appropriately assembled viral particles. Therefore, 
inhibition of HIV-1 protease represents an important aspect for antiviral therapy (Klos 
et al., 2009). 
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Fluorescence resonance energy transfer (FRET) assays have become a popular and 
effective means for drug screening. The assay functions by utilizing a FRET peptide, 
where the sequence is derived from the native p17/p24 cleavage site on Pr-gag for 
HIV-1 protease. In the FRET peptide, the green fluorescence is quenched by an 
appropriate fluorescence quencher until this peptide is cleaved into two separate 
fragments by HIV-1 protease at the cleavage site. Upon cleavage, the green 
fluorescence is recovered and can be monitored at excitation/emission of 490 nm/530 
nm (Roche, Germany). 
 
Although the FRET assay has proven to be very effective, a novel method for HIV-1 
protease detection was recently published by Esseghaier et al., 2012. They designed 
a very simple and inexpensive sensing surface for impedimetric HIV-1 protease 
detection. The principle of the method is based on the utilization of a probe consisting 
of a specific HIV-1 protease substrate peptide which has a magnetic bead attached to 
its N-terminus. This probe is then attached onto a gold sensor surface at the C-
terminus of the same peptide, resulting in a layer of magnetic beads close to the 
sensor surface. Upon cleavage of the probe peptide by the HIV-1 protease, the 
physical link between the magnetic beads and the sensor surface is broken. An 
externally applied magnetic field accelerates the dissociation of the magnetic beads 
from the sensor surface, resulting in a significant shift of the electrochemical signal 
due to the protease induced release of the magnetic beads from the sensor. This 
system showed very high specificity and sensitivity, capable of detecting HIV-1 
protease at a concentration of 10 pg/mL in 25 min. The sensor was also capable of 
detecting the inhibitory activities of the anti-HIV drug Saquinavir mesylate with great 
accuracy, providing a novel approach to high throughput drug screening (Esseghaier 
et al., 2012). 
 
1.4.3 Cytotoxicity Assay (MTT Assay) and Synergistic effects 
1.4.3.1 Cytotoxicity  
The MTT assay is a colorimetric assay where the reduction of 3-(4,5-dimethythiazol-2-
yl)-2,5-diphenyl tetrazolium bromide (MTT), which is a yellow colour, by succinate 
dehydrogenase is measured (Wilson, 2000; Cory et al., 1991). MTT is reduced to an 
insoluble, dark purple, formazan product and this will only occur if the cells are viable. 
The total amount of formazan product is measured spectrophotometrically once the 
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formazan product has been dissolved in a suitable organic solvent such as 
isopropanol. MTT is reduced by metabolically active cells after exposure to a particular 
toxin or treatment (Wilson, 2000; Cory et al., 1991). A main application allows one to 
assess the viability and the proliferation of cells. It can be used to determine 
cytotoxicity of potential medicinal agents and toxic materials, since those agents would 
either stimulate or inhibit cell viability and growth. When the amount of the purple 
formazan produced by cells that have been exposed to a treatment is compared with 
the amount of formazan produced by the untreated control cells, the effectiveness of 
that treatment in causing death or changing the metabolism of the cells can be 
deduced through the production of a dose response curve (Wilson, 2000; Cory et al., 
1991). 
 
1.4.3.2 Synergistic effects 
Treating bacterial infections with antibiotics is beneficial but their mis-use has led to an 
increase in resistance among microorganisms as well as to the re-emergence of old 
infectious diseases (Chanda and Rakholiya, 2011). One approach to treat infectious 
diseases is the use of plant extracts individually and, as an alternative approach, using 
them in combination with antibiotics. This latter approach is referred to as combination 
or synergistic therapy, and applying this new found approach against resistant 
microorganisms may lead to novel ways of treating infectious diseases and is found to 
be even more effective for patients with serious infections caused by drug resistant 
pathogens, such as TB and HIV (Chanda and Rakholiya, 2011). These synergistic 
effects may be due to certain complex formation which becomes more effective in the 
inhibition of a particular species of microorganisms either by inhibiting the cell wall 
synthesis or by causing its lysis or death (Chanda and Rakholiya, 2011). 
 
1.5 PLANT MEDICINES FOR TREATMENT OF TB AND HIV 
 
1.5.1 Annona muricata L. 
Annona muricata L. (Annonaceae), commonly known as soursop, is found from 
Central America to South America, including the North, Northeast and Southeast 
regions of Brazil and Central Africa. It is a small, tropical evergreen tree, 5–6 m high, 
with large dark green leaves. It produces a large edible fruit which is yellow/green in 
colour. Traditionally, the leaves are used for headaches, insomnia, cystitis, liver 
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problems, diabetes, hypertension and as an anti-inflammatory, anti-spasmodic and 
anti-dysenteric (de Sousa et al., 2010). 
  
The extracts of the leaves have parasiticide, anti-rheumatic and anti-neuralgic effects 
when used internally, while the cooked leaves, applied topically, fight rheumatism and 
abscesses (de Sousa et al., 2010). A. muricata has also been investigated for 
accessory substances present in the acetogenins, which is a unique class of 
secondary metabolites that have been isolated from different parts of the plant. Many 
of these acetogenins have been found in the leaves such as annomuricins A and B 
(de Sousa et al., 2010; Aminimoghodamfarouj et al., 2011). These acetogenins have 
cytotoxic properties against tumour cell lines, molluscicidal activity, anti-parasitic, 
insecticidal, immunosuppressive effects and anti-oxidant properties and is regarded as 
a likely source for the development of potential drugs (de souse et al., 2010; 
Aminimoghodamfarouj et al., 2011).  
 
Annonacin is found in the fruits of A. muricata. Along with other acetogenins, 
annonacin is reported to block mitochondrial complex I (NADH dehydrogenase), which 
is responsible for the conversion of NADH–NAD+ and the build up of a proton gradient 
over the mitochondrial inner membrane. This effectively disables a cell’s ability to 
generate ATP via an oxidative pathway, ultimately forcing a cell into apoptosis or 
necrosis (Aminimoghodamfarouj et al., 2011). 
 
1.5.2 Artemisia afra 
Artemisia afra (Asteraceae) is one of the most popular and commonly used herbal 
medicines in South Africa. Artemisia afra is a perennial woody shrub, which grows up 
to 2 m tall with a leafy, hairy and ridged stem and is very aromatic (Liu et al., 2009). In 
the English language, it is referred to as African wormwood and is usually employed 
for treating various ailments such as coughs, colds, headaches, chills, dyspepsia, loss 
of appetite, gastric derangements, colic, croup, whooping cough, gout, asthma, 
malaria, diabetes, bladder and kidney disorders, influenza, convulsions, fever, heart 
inflammation, rheumatism and is also used as a purgative (Liu et al., 2009 and van 
Wyk, 2008). These uses indicate that A. afra possesses antiviral, antibacterial and 
anti-inflammatory activities. Respiratory infections specifically, are treated through 
inhaling the vapour from boiling leaves. 
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It is widely distributed in southern Africa, such as South Africa, Namibia and 
Zimbabwe. In South Africa, it grows in the northern provinces of Gauteng and Limpopo 
along the eastern parts of South Africa, including Swaziland and Lesotho, to the 
Western Cape in the south (Liu et al., 2009). A. afra is rich in terpenes and is therefore 
likely to have valuable biological activities. From past studies it can be noted that this 
plant has a broad spectrum of inhibitory activity against the organisms such as 
Bacillus, Micrococcus, Streptococcus, Staphylococcus, Acinetobacter, Erwinia, 
Enterobacter, Escherichia coli, Proteus, Pseudomonas, Salmonella, Shigella and 
Yersinia (Liu et al., 2009).  
 
1.5.3 Plants as sources of anti-tuberculosis and anti-HIV agents 
Presently used drug regimens to combat TB infections comprise a combination of 
drugs administered over a period of several months, however patients frequently do 
not complete treatment when the symptoms begin to lessen and thus therapies that 
act faster may enhance patient compliance. In addition, lead structures, with novel or 
more effective mechanisms of action are required urgently to overcome the problems 
of drug resistance (McGaw et al., 2008). Natural products continue to play a role in the 
drug discovery and development process and plants are becoming increasingly 
recognised as a useful source of highly active antimycobacterial metabolites (Pauli et 
al., 2005; Gautam et al., 2007). Many South African plants have ethnobotanical uses 
for the treatment of tuberculosis and its related symptoms such as coughing, 
respiratory ailments and fever.  
 
The only treatment with proven efficacy for HIV is lifelong with the use of antiretroviral 
drugs (ARVs) (Palella et al., 1998; Lamorde et al., 2010). In South Africa it is evident 
that majority of the ARV treatment sites are located in towns and urban centres 
whereas access to treatment in rural areas remains incredibly low and thus access 
and continuation of treatment is difficult. Thus investigations on the biological activity 
of plant extracts against the crucial steps in the establishment of infection with regards 
to HIV Reverse Transcriptase and Integrase would widen the scope of the search for 
plant based anti-HIV molecules. 
 
With the great diversity of plants in South Africa, screening of extracts of these plants 
for antimycobacterial and anti-HIV efficacy has much to offer in the search for novel 
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active metabolites that may be effective against M. tuberculosis and HIV (McGaw and 
Eloff, 2008; McGaw et al., 2008). It is now even more important to further research A. 
afra, as it was recently found by Lubbe et al. (2012) to possess anti-HIV activity at the 
same level as that of its closely related, artemisinin producing relative, Artemisia 
annua. Lubbe et al. (2012) used A. afra as a tea infusion through a method using 
genetically modified HeLa cell lines, which were then infected with HIV. Therefore, 
further determining which enzymes are affected by the plant extract as well as which 
compounds are responsible for this activity would be highly useful in the search for 
novel anti-HIV therapies. 
 
It has been documented that Oleanolic acid (OA), which is a triterpenoid compound 
that exists widely in the human diet, medicinal herbs and various other plants, has 
potent antimycobacterial properties against drug sensitive and drug resistant M. 
tuberculosis and that it has favourable synergistic activity with the first line drugs INH, 
RIF and EMB (Ge et al., 2010). Recently, it has been shown that OA can be modified 
at the C-3 position to form cinnamate based esters which yields high antimycobacterial 
activity. This ability to modify OA may allow the creation of new compounds with more 
effective derivatives and less toxicity (Ge et al., 2010). It might be beneficial to 
determine if A. afra and A. muricata possess OA.   
 
1.6 POTENTIAL PLANT-DRUG INTERACTIONS 
1.6.1 Interactions between plant medicines and drug metabolising pathways 
Drug interactions are caused by four major mechanisms namely, altered drug 
absorption, altered renal elimination, additive effects or toxicities and altered hepatic 
metabolism of drugs (Patel et al., 2011). Drugs are generally absorbed from the 
intestine and can be eliminated too quickly if herbal laxatives are taken. The most 
important pathway for drug metabolism is the family of liver enzymes known as the 
cytochrome P450 group, of which CYP3A4 is the most commonly known and is 
responsible for the metabolism of many drugs, including antiretrovirals (ARVs) (Zhou 
et al., 2007; Patel et al., 2011). The activity of these enzymes may be induced or 
inhibited by the use of traditional medicines. The second most important drug 
interaction in HIV patients on ARVs is altered efflux mechanisms, such as P-
glycoprotein, which is responsible for transporting a range of compounds, including 
protease inhibitors, out of the intestinal epithelial cells and back into the intestinal 
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lumen (Brown et al., 2008; Balayssac et al., 2005; Patel et al., 2011). Hypoxis 
hemerocallidea, commonly used in Southern Africa to boost immunity in HIV patients, 
interacts with the efflux mechanism of nevirapine across intestinal epithelial cells, 
which can result in an increase in the bioavailability of this drug, thus an increase in 
drug toxicity, drug resistance and side effects (Mills et al., 2005; Brown et al., 2008; 
Patel et al., 2011). 
 
It is estimated that more than 80% of the Southern African population makes use of 
traditional medicines, often in combination with prescription drugs (Maduna, 2006). 
Components of medicinal plants can alter the absorption and metabolism of 
conventional drugs leading to the reduced efficacy of the specific drug or systemic 
drug toxicity (Meijerman et al., 2006; Zhou et al., 2007 and Willet et al., 2004). 
 
Traditional remedies are usually complex mixtures of different molecules that are able 
to interact with various drug metabolising pathways, such as the inhibition or 
transcriptional activation of drug metabolising enzymes (Pal and Mitra, 2006). A 
common drug metabolic pathway involves the oxidation of the parent molecule, 
referred to as phase I metabolism, which will then be followed by conjugation of the 
oxidised group  with polar molecules such as glucose, sulphate or glutathione and this 
is referred to as phase II metabolism (Pal and Mitra, 2006).  
 
The major enzymes involved in human phase I metabolism are the different isoforms 
of cytochrome P450, namely CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and 
CYP3A4 (Zhou et al., 2007; Crespi and Stresser, 2000). The latter isoform is the most 
abundant CYP isozyme and is believed to metabolise between 50 and 70% of the 
currently marketed drugs including HIV protease inhibitors, non-nucleoside reverse 
transcriptase inhibitors, macrolide antibiotics and azole antifungals (Pal and Mitra, 
2006). The key phase II enzymes include UDP-dependant glucuronosyl transferase, 
sulfotransferase and glutathione-S-transferase (Meijerman et al., 2006; Triplitt, 2006; 
Mouly et al., 2006).  
 
Since HIV protease inhibitors, macrolide antibiotics and azole are recognised 
substrates or inducers of these drug metabolising proteins, it is clear that plant 
components can adversely affect the course of tuberculosis and HIV treatment (Zhou 
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et al., 2007; Venkataramanan et al., 2006). If plant remedies are used in combination 
with conventional drugs, knowledge on the possible interactions that may occur will 
enable physicians to suggest safe drug regimens, dose adjustment or discontinuation 
of therapy if toxic drug-plant interactions could occur (Zhou et al., 2007; 
Venkataramanan et al., 2006). 
 
Therefore methods employed for the in vitro antimycobacterial and anti-HIV screening 
of natural compounds/ products (plant medicines) are important for validating the 
traditional use of herbal treatments. 
 
1.6.2 Assays to investigate drug metabolising pathways 
CYP450 screening kits are designed to assess the metabolism and inhibition of the 
major human P450 isozymes involved in hepatic drug metabolism, namely CYP1A2, 
CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP3A5. The kit will 
employ CYP450 substrates and CYP450 baculosomes reagents. The CYP450 
baculosomes reagents are microsomes prepared from insect cells expressing a 
human P450 isozyme and rabbit NADPH-P450 reductase 
(www.tools.invitrogen.com/downloads/O-13873-r1_US_0405.pdf).  
 
CYP450 baculosomes reagents offer a distinct advantage over human liver 
microsomes in that only one CYP450 enzyme is expressed, thereby preventing 
metabolism by other CYP450s. The substrates are metabolized by a specific CYP450 
enzyme into products that are highly fluorescent in aqueous solutions. The fluorescent 
metabolites are excited in the visible light spectrum, which minimizes interference 
caused by the background fluorescence of UV excitable compounds and NADPH. Due 
to the functioning of the kit and the specific substrates that are used, even weak 
CYP450 inhibitors will be determined (www.tools.invitrogen.com/downloads/O-13873-
r1_US_0405.pdf). 
 
There are multiple drugs that can be utilized to help reduce the symptoms of 
HIV/AIDS. Such drugs include tenofovir, emtracitbine, efavirenz, nevirapine, 
zidovudine, lamivudine, lopinavir and ritonavir for the treatment of HIV/AIDS. Drugs 
utilized for TB include ofloxacin, streptomycin, ethambutol, rifampicin and isoniazid, all 
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of which are utilized in primary healthcare in South Africa. Of these drugs only a few 
have an effect on the CYP450 isozymes. These drugs include  efavirenz, which is 
metabolized mostly by CYP3A4 and CYP2B6 but also inhibits CYP2C9 and 
CYP2C19; nevirapine, which is oxidatively metabolised by CYP3A4 and CYP2B6; 
lopinavir, which also undergoes oxidative metabolism by  the CYP3A4 isozyme; 
ritonavir, which is metabolized by CYP3A4 and CYP2D6, however this may not be a 
good choice of drug as it both induces and inhibits the expression of CYP3A4; 
isoniazid, which inhibits CYP1A2, CYP2C9, CYP2C19 and CYP3A4 and rifampicin, 
which induces the isozyme CYP2C8 (Levien et al., 2003). 
 
Glutathione-S-transferases are thought to play a role in initiating the detoxification of 
potential alkylating agents including pharmacologically active compounds. These 
enzymes catalyze the reaction of such compounds with the -SH group of glutathione, 
thereby neutralizing their electrophilic sites and rendering the products more water 
soluble (Habig et al., 1974). Glutathione conjugates are thought to be metabolized 
further by cleavage of the glutamate and glycine residues, followed by acetylation of 
the resultant free amino group of the cysteinyl residue, to produce the final product, a 
mercapturic acid. The mercapturic acids are then excreted (Habig et al., 1974). A 
widely used method for determining GST activity in living cells is by utilizing 1-Chloro-
2,4-dinitrobenzene (CDNB) which is suitable for the broadest range of GST isozymes.  
Addition of CDNB to the cell culture medium and conjugation of the thiol group of 
glutathione to the CDNB substrate, results in an increase in the absorbance at 340 nm 
(www.sigmaaldrich.com/etc/medialib/docs/Sigma/Bulletin/cs0410bul.Par.0001.File.tmp
/cs0410bul.pdf).  
 
 
 
 
 
 
 
 
 
 
19 
1.7 SCOPE AND OBJECTIVES 
Current drug regimens to combat TB and HIV infections comprise multiple drugs 
administered over several months, hence patients frequently do not complete the 
treatment. New antimycobacterial and anti-HIV therapies that act faster may enhance 
patient compliance.  
 
Many plant species are used in traditional South African medicine to alleviate 
symptoms of TB and HIV and several lead compounds have been reported for further 
research following in vitro antimycobacterial and antiretroviral activity evaluation (Klos 
et al., 2009). A. muricata and A. afra are two plants which were investigated for 
inhibitory activity against M. tuberculosis and HIV. A. afra is one of the most popular 
and commonly used herbal medicines in southern Africa to treat diseases such as 
herpes simplex virus, asthma and several others. Despite its popularity, A. afra has 
been poorly researched and thus has limited ethnopharmalogical support (Liu et al., 
2009 and Lubbe et al., 2012).  
 
There are few reports on A. muricata, which indicate that all parts of the tree have 
been used to treat multiple disorders (Boyom et al., 2011). The leaves are especially 
used as an antispasmodic, sedative, also for coughs, grippe, asthma, catarrh and 
asthenia (Asprey and Thornton, 1955). As both plants have been shown to be used 
traditionally against chest infections, respiratory ailments and other viruses, it was 
relevant to determine if any activity was present against the two major diseases in 
South Africa namely TB and HIV. 
 
1.7.1 Hypotheses to be tested 
It was hypothesised that A. muricata and A. afra may have an inhibitory effect on M. 
tuberculosis and the Human Immunodeficiency Virus. 
 
It was further hypothesized that possible drug interactions may occur with plant 
extracts and drugs used for treatment of TB and HIV which may interfere with drug 
metabolizing pathways involving the CYP3A4 isozyme and Glutathione-S-
Transferases. 
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1.7.2 Objectives 
The following objectives were established to test the above hypothesis: 
 To screen two plant extracts (A. muricata and A. afra) for in vitro inhibitory activities 
against M. tuberculosis and Human Immunodeficiency Virus enzymes  
 To determine cytotoxicity and possible synergistic effects of plant extracts, and 
 To investigate drug interactions with plant extracts and drugs used for M. 
tuberculosis and HIV treatment. 
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CHAPTER TWO 
 
MATERIALS AND METHODS 
 
2.1. BACTERIAL STRAINS, GROWTH CONDITIONS AND MEDIA 
M. tuberculosis H37Rv ATCC 27294 was used as a control culture for all assays as it 
has a drug susceptibility profile fairly representative of most drug susceptible clinical 
isolates. M. tuberculosis was grown in Middlebrooks 7H9 broth [88.95 mL ddH2O; 
0.470 g BD DifcoTM Middlebrooks 7H9 broth base; 0.8 mL glycerol (Merck); 0.005 mL 
Tween® 80 (Sigma-Aldrich), 1 mL Middlebrook Albumin-dextrose-catalase (ADC) 
growth supplement (Sigma-Aldrich) added after autoclaving]. Cultures were  incubated 
at 37oC for 10 days after which the turbidity of the culture was assessed and adjusted 
to a McFarland 0.5 standard (1.5 x 108 cells/mL) [1.175% BaCl2 (0.1175 g in 10 mL 
ddH2O) and 1% H2SO4 (0.5 mL H2SO4 in 50 mL ddH2O)]. 
 
2.2 CONTROL DRUGS: M. TUBERCULOSIS 
The following antibiotics (Sigma-Aldrich) that are currently used for treatment of M. 
tuberculosis infections were tested and used as positive controls for optimization of all 
bioassays: ofloxacin (OFX), isoniazid (INH), rifampicin (RIF), streptomycin (ST) and 
ethambutol (EMB). All drugs were solubilized according to the manufacturer’s 
instructions either in dimethyl sulfoxide (DMSO) (Merck), distilled water or 0.1 N NaOH 
(1 g NaOH in 250 mL ddH2O) and stock solutions (1 mg/mL) were filter sterilized (0.2 
µm filter) and stored in 1 mL aliquots at -20oC until required. 
 
2.3 PREPARATION OF PLANT EXTRACTS 
Annona muricata L. was air dried for two days followed by drying in a hot air oven at 
40°C, then ground into powder and stored. One hundred grams of powdered plant 
material was macerated with 80% ethanol at room temperature. The extract was then 
filtered and concentrated to dryness in vacuo at room temperature (Sowemimo et al., 
2009). 
 
Fresh leaves of the Artemisia afra plant were blended and separated into two batches. 
The one batch was submerged in ddH2O and the second batch submerged in 80% 
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absolute ethanol. These were then placed in the dark at room temperature overnight. 
After incubation, the two batches were filtered using a 0.1 µm Whatman filter paper, in 
order to obtain a sediment free liquid filtrate. The aqueous batch was collected in a 50 
mL Falcon tube whereas the ethanol batch was placed in a 50 mL flask and placed 
over a water bath at 35°C where nitrogen gas was used to evaporate any excess 
ethanol. The remainder of the extract was then re-constituted in water so as to obtain 
an ethanol concentration of less than 5%. This was then placed into a 30 mL Falcon 
tube and frozen at -80°C overnight. These samples were then placed in freeze drying 
flasks and freeze dried for three days. 
 
2.4 MICROPLATE ALAMAR BLUE ASSAY (MABA) 
This assay was performed as described by Franzblau et al. (1998); Lougheed et al. 
(2009) with modifications. Clear 96 well plates (Corning, Scientific Group) were used 
initially, and for fluorimeter readings, contents were transferred to black plates. Outer 
perimeter wells were filled with sterile water to minimize evaporation of the medium in 
experimental wells during incubation. The wells in rows B to G in columns 3 to 11 
received 100 µL of Middlebrooks 7H9 broth (prepared as described in 2.1, but without 
Tween® 80). One hundred microlitres of drug to be tested was added to wells in rows 
B to G in columns 2 and 3. This was followed by the transfer of 100 µL from column 3 
to column 4 and the contents of the wells mixed well. Identical serial 1:2 dilutions were 
continued through to column 10 and 100 µL of excess medium was discarded from the 
wells in column 10. Final drug concentration ranges were as follows: OFX and RIF, 
0.0625 to 8.0 µg/mL; INH, 0.125 to 16.0 µg/mL; EMB and SM, 0.25 to 32 µg/mL. M. 
tuberculosis inoculum (100 µL of 1x108 cells/well) was added to the wells in rows B to 
G in columns 3 to 11. Wells in column 2 served as a drug only control to detect auto-
fluorescence of compounds and to determine whether the compounds have any effect 
on the alamar blue dye. Wells in column 11 served as a bacterial growth control. 
Plates were sealed with clear microplate sealing tape (Scientific Group) and incubated 
at 37°C for 7 days. On day 7, 20 µL of alamar blue reagent (CellTiter-Blue, Promega) 
and 12.5 µL 20% Tween® 80 was added to each well. Plates were observed after 6 h 
and incubated for a further 18 h as the colour change was not sufficient. A blue colour 
in the well was interpreted as no growth and a pink colour was scored as growth. The 
MIC was defined as the lowest drug concentration which prevents a colour change 
from blue to pink.  
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Due to the biosafety hazard of M. tuberculosis aerosols, the M. tuberculosis cells were 
killed using 10% formaldehyde after addition of alamar blue dye reagent. The 
fluorescence (relative fluorescence units, RFU) was then measured using a plate 
reader at 535 nm excitation and 590nm emission (Reis et al., 2004).  
 
Percent inhibition was defined as: 
Percent inhibition = 1 – (test well RFU/ mean RFU triplicate bacteria only well) x 100 
MIC was taken to be the lowest concentration of a drug capable of causing ≥90% 
inhibition compared to the untreated bacteria only controls (Collins and Franzblau, 
1997). 
 
2.5 P-IODONITROTETRAZOLIUM CHLORIDE (INT) ASSAY  
This assay was carried out as described by Eloff, (1998) using p-Iodonitrotetrazolium 
chloride (INT) dye. One hundred microliters of Middlebrooks 7H9 broth [supplemented 
with 10% albumin dextrose catalase (ADC), 1000 µg/mL of sodium nitrate (NaNO3) 
and 0.05% Tween® 80] were added to wells of a sterile 96-well plate from columns 3 
to 11. Drug concentration ranges were: RIF (0.01563 - 2.0 µg/mL); OFX (0.03125 - 4.0 
μg/mL); INH (0.003125 - 0.4 µg/mL); EMB (0.1172 - 15 µg/mL) and SM (0.01563 - 2.0 
μg/mL). Drug (100 µL) was added to wells in columns 2 and 3.  This was followed by 
transfer of 100 µL from column 3 to column 4 and serially diluted (2-fold dilutions) up 
to column 10. Columns 11 and 12 contained 100 and 200 µL of medium without drugs, 
respectively and served as the growth and medium controls respectively. The bacterial 
suspension (100 μL) (1.5 x 108 cells/ well) was added to wells in columns 3 to 11 to 
give a final volume of 200 µL per well. All plates were then sealed with microplate 
sealing tape and incubated at 37°C for 7 days after which 40 μL of 0.2 mg/mL INT dye 
(Sigma) was added to each well and left to incubate for 30-60 minutes after which if no 
colour change was observed, incubated for a further 23 hours. Viable bacteria reduce 
the yellow dye to a purple/pink colour and no colour change indicated inhibition of 
bacterial growth.  
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2.6 FLOW CYTOMETRY 
Flow cytometry analysis was conducted using fluorescein diacetate (FDA) according 
to the methods of Norden et al. (1995); Reis et al. (2004); Kirk et al. (1998) with 
modifications. M. tuberculosis culture [500 µL - equivalent to a McFarland 0.5 standard 
(1.5 x 108 bacteria)] was inoculated into freshly prepared Middlebrook 7H9 broth 
containing the following antibiotics and their concentration ranges respectively: OFX 
and RIF, 0.0625 to 8.0 µg/mL; INH, 0.125 to 16.0 µg/mL; EMB and SM, 0.25 to 32 
µg/mL. Drug-free growth controls and all tubes with antibiotics and broth cultures were 
incubated at 37°C for 72 hours. After incubation, 500 µL of each assay suspension 
was incubated for 1 h at room temperature with 100 µL of a 10% solution of 
formaldehyde to inactivate the M. tuberculosis cells. Formaldehyde inactivated M. 
tuberculosis cells (500 µL) were then centrifuged for 60 sec at 12000xg to pellet the 
cells. The supernatant was removed and the pellet re-suspended in 250 µL IsoflowTM 
EPICSTM Sheath fluid (Beckman Coulter). Prior to analysis, the cell suspension was 
vortexed, passed through a Neomedic 25 gauge micro-emulsifying needle 
(Separations), and vortexed again to ensure complete separation of the cells, and to 
avoid clumping. The cells were re-suspended by repeated pipetting and transferred to 
a cell flow cytometry tube. This re-suspension step was repeated. The re-suspended 
mixture (200 µL) was then incubated with 200 µL FDA (freshly prepared) at 500 ng/mL 
in phosphate buffered saline at pH 7.4. The samples were then incubated at 37°C for 
30 min before being analysed with a flow cytometer (Beckman Coulter FC500). 
Samples were analysed by histogram profiles of FDA fluorescence and 2 parameters 
were evaluated: events per minute (number of labelled mycobacteria) and mean 
channel fluorescence (intensity of fluorescence-labelled mycobacteria).  
 
2.7 DETECTION OF ANTI-HIV REVERSE TRANSCRIPTASE ACTIVITY USING A 
NON-RADIOACTIVE ELISA KIT 
The potential of plant extracts to inhibit reverse transcriptase was determined as 
outlined by Klos et al. (2009), with modifications, using a non-radioactive HIV-Reverse 
Transcriptase (RT) colorimetric ELISA kit from Roche Diagnostics. For the assay, 
reverse transcriptase was reconstituted in autoclaved re-distilled water to give a final 
concentration of 2 ng/µL stock. In a separate reaction tube, 1 µL of this stock solution 
was diluted with 19 µL of lysis buffer. Twenty microlitres of the extract samples and 
positive control, Nevirapine (Aspen), diluted to the required concentrations using lysis 
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buffer was then added to the respective tubes. The concentration range was the same 
for all extracts and for Nevirapine: 0.2 to 4 mg/mL. Twenty microlitres of prepared 
reaction mixture was then added to each tube. This was incubated for 1 h at 37°C. 
Controls included a background control containing lysis buffer alone, a negative 
control for inhibition which included HIV-1 RT with only lysis buffer and reaction 
mixture with no inhibitors, a solvent control which contained HIV-1 RT with only 
solvent (4% DMSO) in lysis buffer. After incubation, the total volume (60 µL) was 
transferred from each reaction tube to a well of a streptavidin coated module, covered 
with a cover slip and incubated for 1 h at 37°C. After incubation, the solution was 
removed from the wells and rinsed 5 times with 250 µL of washing buffer for 30 
seconds each. Two hundred microlitres of freshly prepared anti-DIG-POD was then 
added to each well. The plate was covered with a cover slip and incubated for 1 h at 
37°C. After incubation, the solution was removed and the rinsing step was repeated. 
Two hundred microlitres of ABTS (2, 2'-Azino-Bis-3-Ethylbenzothiazoline-6-Sulfonic 
Acid) substrate solution was then added to each well and incubated at room 
temperature for 10-20 minutes. The absorbance was measured at 405 nm using a 
microplate reader. The HIV-RT inhibition by the plant extracts was measured as a 
percentage of the inhibition that occurred with HIV-1 RT in the absence of an inhibitor 
in the same solvent (4% DMSO) as the extracts. 
 
2.8 DETECTION OF ANTI-HIV-1 INTEGRASE ACTIVITY 
The potential of plant extracts to inhibit HIV-1 integrase was measured according to 
the manufacturer’s instructions using a non-radioactive HIV-1 integrase colorimetric kit 
supplied by XpressBio. For the assay, 100 µL of donor substrate (DS) DNA was 
added to each well and subsequently incubated for 30 min at 37°C. The liquid was 
removed from the plates and washed 5 times with 300 µL of 1x wash buffer. Two 
hundred microlitres of blocking buffer was added to each well and incubated for 30 
min at 37°C. The liquid was then aspirated from the wells and subsequently washed 3 
times with 200 µL of reaction buffer. The integrase enzyme was diluted 1:300 with 
reaction buffer before use, after which 100 µL of the diluted integrase was added to 
each well and incubated for 30 min at 37°C. The liquid was then aspirated from the 
wells and washed 3 times with 200 µL of reaction buffer. Fifty microlitres of the extract 
samples and positive control, sodium azide, at 2x the required concentrations using 
reaction buffer, were then added to the respective wells and incubated for 5 min at 
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room temperature. The concentration range was the same for all extracts: 0.025-4 
mg/mL. Controls included a background control, which contained reaction buffer 
alone, while the negative control for inhibition included HIV-1 integrase with only 
reaction buffer with no inhibitors, a solvent control which contained HIV-1 integrase 
with only solvent (4% DMSO) in reaction buffer. After incubation, 50 µL of target 
substrate (TS) DNA was added to each well and gently mixed. The plate was then 
incubated for 30 min at 37°C. The liquid was removed and the wells washed 5 times 
with 300 µL of wash buffer. One hundred microlitres of horseradish peroxidase (HRP) 
antibody solution was added to each well and incubated for 30 min at 37°C. The liquid 
was then removed and washed 5 times with 300 µL of wash buffer after which 100 µL 
of 3,3', 5,5'-tetramethylbenzidine (TMB) peroxidase substrate solution was added to 
each well and incubated for 10 min at room temperature. One hundred microlitres of 
TMB stop solution was then added to each well, which caused a colour change from 
blue to yellow at various intensities. The absorbance was measured at 450 nm using a 
microplate reader. The HIV integrase inhibition by the plant extracts was measured as 
a percentage of the inhibition that occurred with HIV-1 integrase in the absence of an 
inhibitor in the same solvent (4% DMSO) as the extracts. 
 
2.9 CYTOTOXICITY OF PLANT EXTRACTS 
 
2.9.1 Cell culture conditions and Cytotoxicity testing 
The adherent liver cell line, Chang Liver cells, and the adherent hepatocellular cell 
line, HepG2 were used for the experimental procedures. The cells were routinely 
maintained in 10 cm culture dishes without antibiotics in Eagle's Minimal Essential 
Medium (EMEM) supplemented with non-essential amino acids (NEAA) and 10% 
foetal bovine serum (FBS) and incubated in a humidified 5% CO2 incubator at 37ºC.   
 
Cytotoxicity was determined using the MTT (4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) assay. A 10 cm culture dish containing either Chang liver or 
HepG2 cells was removed from the incubator and the monolayer subsequently 
trypsinised. Cells were suspended in EMEM supplemented with 10% FBS and NEAA 
to give 150,000 cells/mL (30 000 cells/well) and then seeded into a 96 well plate, (200 
µL suspension per well) and incubated overnight to allow the cells to attach. After 
incubation, the spent medium was removed and 200 µL of fresh EMEM supplemented 
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with 10% FBS and NEAA containing the plant extracts at concentrations ranging 
between 3.91 and 250 μg/mL was then added to the wells in triplicate. Both cell lines 
were incubated at 37°C in a humidified 5% CO2 incubator for 24 and 48 hours.  After 
the incubation, the medium was aspirated and replaced with 200 µL of fresh EMEM 
supplemented with 10% FBS and NEAA containing 0.5 mg/mL MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] and subsequently incubated for 
3 hours. The medium was then removed and the MTT crystals solubilised by addition 
of 200 µL dimethyl sulfoxide (DMSO). The absorbance was then read at 540 nm using 
a BioTek® PowerWave XS spectrophotometer (Winooski, VT, USA).  
 
2.9.2 Potential for Synergistic hepatotoxicity between Plant Extracts and 
Rifampicin 
The adherent liver cell line, Chang liver, and the adherent hepatocellular cell line, 
HepG2, were used to investigate potential synergism. Cells were routinely maintained 
in 10 cm culture dishes, in Eagle's Minimal Essential Medium (EMEM), without 
antibiotics, supplemented with non-essential amino acids (NEAA) and 10% foetal 
bovine serum (FBS) and incubated in a humidified 5% CO2 incubator at 37ºC. 
 
Synergistic testing was conducted by calculating the combination index (CI) according 
to the method outlined by Chou (2010).  A 10 cm culture dish containing either Chang 
liver cells or HepG2 cells was removed from the incubator and the monolayer 
subsequently trypsinised. An appropriate volume of cells was suspended in EMEM 
supplemented with 10% FBS and NEAA to give 150,000 cells/mL (30 000 cells/well) 
and these were then seeded into a 96 well plate, using 200 µL suspension per well 
and incubated overnight to allow the cells to attach.  
 
After incubation, the spent medium was removed and 200 µL of fresh EMEM 
supplemented with 10% FBS and NEAA containing the combined plant extract and 
antibiotics at a fixed ratio, which was determined empirically using the following 
equation: 
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Where (a) represents the plant extract and (b) represents the antibiotic, in this case 
rifampicin. 
 
The above equation calculates the total concentration that was present in each well. 
This concentration was then divided by the fixed ratio, previously determined based on 
the respective IC50 values of the extracts and the antibiotic obtained from cytotoxicity 
tests, to determine the concentration of each component individually. Serial dilutions 
were made to obtain the appropriate concentration range. The plates were incubated 
for 24 hours and IC50 of the new combination was determined. The combination index 
was calculated using the following equation: 
 
    
  
        
  
  
       
 
 
Where Ca is the IC50 of the combination mixture plotted on an axis using the respective 
antibiotic concentrations, Cb is the IC50 of the combination mixture plotted on an axis 
using the respective plant extract concentrations. A combination index greater than 1, 
indicated a potential antagonistic relationship, and a value less than 1 indicated a 
synergistic relationship.  A value of 1 implies that the two components produced a 
purely additive effect.   
 
In order to obtain a full spectrum of whether synergistic effects were present at all 
concentrations of the extracts and the antibiotic, the above experiments were repeated 
using an IC25 and IC70. 
 
2.10 INTERACTIONS OF PLANT EXTRACTS WITH DRUG METABOLIC 
PATHWAYS 
 
2.10.1 CYP3A4 Inhibition Assay 
 
The CYP3A4 inhibition assay was conducted according to the manufacturer’s 
instructions (Life Technologies). The CYP3A4 baculosomes, regeneration system and 
NADP+ was thawed at room temperature and kept on ice until ready to use. The 
CYP3A4 baculosomes and regeneration system was mixed gently after thawing. The 
assay conditions for screening was performed as indicated in Table 2.1. 
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Table 2.1:  Assay Conditions (Life Technologies, USA). 
 
Condition Purpose Dispensing 
Test Compound Screen for inhibition by compound of 
interest 
40 μL 2.5X test compound 
50 μL Master Pre-Mix 
10 μL Substrate and NADP
+ 
Positive Inhibition 
Control 
Inhibit the reaction with a known P450 
inhibitor - Ketoconazole 
40 μL 2.5X positive inhibition control 
50 μL Master Pre-Mix 
10 μL Substrate and NADP
+ 
Solvent Control  
(No Inhibitor) 
Accounts for possible solvent inhibition 
caused by introduction of test 
compounds originally dissolved in an 
organic solvent such as DMSO 
40 μL 2.5X solvent control 
50 μL Master Pre-Mix 
10 μL Substrate and NADP
+ 
Background Enables subtraction of background 
fluorescence during data analysis 
40 μL 2.5X solvent control 
50 μL CYP450 Reaction Buffer 
10 μL Substrate and NADP+ 
 
 
The substrate was reconstituted using anhydrous acetonitrile according to Table 2.2. 
The fluorescent standard was reconstituted using DMSO. These solutions, once 
prepared, were then stored at room temperature for immediate use or at -20°C for 
long term use. 
 
Table 2.2:  Reconstitution of the CYP3A4 substrates (Life Technologies, USA). 
 
Isozyme 
Type 
CYP450 
Substrate 
mg/ tube μmol/ tube μL acetonitrile 
added per tube 
[stock solution] 
(mM) 
[screening conc.] 
(μM) 
3A4 BOMR 
(benzyloxymet
hylresorufin) 
0.1 0.30 150 2 3 
 
The 2X CYP3A4 reaction buffer was diluted with nanopure water to a desired 
concentration of 100 mM. This was used for the preparation of standards, inhibitors, 
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master pre-mix and substrate/NADP+ solutions. The diluted reaction buffer was stored 
at room temperature. 
 
In order to determine the IC50, a 2.5X dilution of the test compounds was prepared as 
well as a 2.5X solution of a known CYP3A4 inhibitor, ketoconazole, which acted as the 
positive control. The solvent, which was used to dissolve the test compounds, and 
ketoconazole, was prepared at 2.5X the final concentration. Forty microliters of the 
2.5X solutions prepared above was then added to desired wells of the 96 well plate 
and this was conducted in triplicate. 
 
The master pre-mix was then prepared by diluting the CYP3A4 baculosomes reagent 
and regeneration system in 1X CYP3A4 Reaction Buffer according to the values seen 
in Table 2.3. The solutions were kept at room temperature for immediate use. After 
preparation of the master pre-mix, 50 μL was added to each well and mixed. 
 
Table 2.3:  Master pre-mix preparation for the CYP3A4 isozyme (Life Technologies, USA). 
 
Isozyme 
Type 
CYP450 
Substrate 
µL of CYP450 
Reaction 
Buffer (2X) 
added 
μL of 
Regeneration 
System (100X) 
added 
μL of CYP450 
Baculosomes 
added 
Conc. Of CYP450 
in Master pre-mix 
(2X), nM 
Screening 
conc of 
CYP450, nM 
3A4 BOMR 4850 100 50 10 5 
 
The plates were then incubated for 10 minutes at room temperature to allow the 
compounds to interact with the CYP3A4 in the absence of enzyme turnover. During 
this pre-incubation, the pre-mixture of 10X substrate and NADP+ was prepared 
according to Table 2.4. 
 
Table 2.4:  Preparation of the substrate and NADP
+
 (Life Technologies, USA). 
 
Isozyme 
Type 
CYP450 
Substrate 
μL of CYP450 Reaction 
Buffer (1X) added 
μL of Reconstituted 
Substrate added  
μL of NADP
+
 
(100X) added  
3A4 BOMR 885 15 100 
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The reaction was then started by adding 10 μL per well of the 10X substrate and 
NADP+ mixture prepared above and the entire solution mixed. The plate was 
transferred into the fluorescent plate reader and the fluorescence monitored over time 
at excitation and emission wavelengths listed in Table 2.5. Readings were taken at 1 
minute intervals over a period of 60 minutes. 
 
Table 2.5: Excitation and emission wavelengths for the various fluorescent standards (Life 
Technologies, USA). The red fluorescent standard was used for this specific experiment. 
 
 
 
Red Standard was sodium salt or resorufin. Blue Standard was 3-cyano-7-
hydroxycoumarin. Cyan Standard was 7-hydroxy-4-trifluoromethylcoumarin. Green 
Standard was fluorescein. 
 
The reaction rates were then obtained by calculating the change in fluorescence per 
unit time and the percent inhibition due to presence of test compound or positive 
inhibition control were calculated using the equation below: 
 
              
     
 
       
 
Where X is the rate observed in the presence of the test compound, A is the rate 
observed in the absence of inhibitor and extract. 
 
2.10.2 Glutathione-S-Transferase Inhibition Assay 
 
Glutathione-S-Transferase (GST) inhibition by the plant extracts was conducted using 
the Glutathione-S-Transferase assay kit, with modifications, supplied by Sigma. 1-
 Fluorescent Standard 
Red Blue Green Cyan 
Fluorescence 
Plate Reader 
Excitation/ 
Emission 
Center 
(nm) 
Band 
width 
Center 
(nm) 
Band 
width 
Center 
(nm) 
Band 
width 
Center 
(nm) 
Band 
width 
With Filters Excitation 535 25 415 20 485 20 415 20 
Emission 590 20 460 20 520 25 420 45 
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Chloro-2,4-dinitrobenzene (CDNB) was used as the substrate as it is suitable for a 
wider range of GST enzymes. Human placental GST (Sigma) was purchased 
separately to be used in the assay in order to determine inhibition or stimulation, as 
opposed to GST production. A substrate master mix was prepared according to the 
amount of assays that needed to be conducted. Generally, a 10 mL master mix was 
sufficient for 50 assays and contained 9.8 mL of Dulbecco’s Phosphate Bufferred 
Saline (DPBS), 0.1 mL of 200 mM reduced L-Glutathione and 0.1 mL of 100 mM 
CDNB. Initial experiments were conducted to determine optimal GST activity and 
optimal extract concentrations that will not be too dark to be measured at an 
absorbance of 340 nm. The optimal amount of GST was found to be 55 units/mL. The 
optimal extract concentrations that gave reasonable readings were 0.0625 and 
0.03125 mg/mL. One hundred and eighty six microlitres of the substrate master mix 
was added into the required wells of a 96 well microplate. Ten microlitres of the plant 
extracts at the required concentrations was then added. Lastly, 4 µL of GST at 55 
units/mL was added and placed immediately in the plate reader and the absorbance 
was measured at 340 nm every minute for 30 minutes. Upon conjugation of the thiol 
group of glutathione to the CDNB substrate, there is an increase in absorbance. 
Controls included a negative control, which contained only substrate master mix, a 
positive GST control, which contained GST with no inhibitors and then a positive 
control for GST inhibition, which was ethacrynic acid (2 µg/mL) as it is a known 
inhibitor of GST.  
 
2.11 STATISTICAL ANALYSIS 
Significance determinations were obtained by applying Tukey's HSD test. All results 
with P < 0.05 were considered significant. IC50 values were calculated using GraphPad 
Prism Version 5.0. 
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CHAPTER THREE 
 
INHIBITORY ACTIVITIES AGAINST Mycobacterium tuberculosis AND 
HUMAN IMMUNODEFICIENCY VIRUS  
 
3.1 INTRODUCTION 
 
Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis, 
which most commonly affects the lungs and is transmitted from person to person via 
droplets from the throat and lungs of people with the active respiratory disease (Tekwu 
et al., 2012). In 2011, TB remained the second cause of death from infectious disease 
worldwide. In 2010, according to the World Health Organization (WHO), TB incidence 
and prevalence were estimated at 8.8 and 12 million cases respectively. A total of 1.1 
million among HIV-negative people and 0.35 million among HIV-positive people died 
from TB in the same year (Villemagne et al., 2012, WHO, 2011). The association with 
the HIV epidemic, the increasing emergence of multi-drug resistant TB (MDR-TB) and 
extensively drug resistant TB (XDR-TB) have worsened the situation and posed a 
serious health threat (Rattan et al., 1998; Tekwu et al., 2012). TB is treatable but 
curing multi-drug resistant TB (MDR-TB) is very difficult and often requires very long 
courses of toxic drugs, thereby, raising serious problems of compliance (WHO, 2009). 
 
There is an urgent need to search for alternative antituberculosis drugs. Medicinal 
plants have become the focus of intense study recently in terms of conservation and 
as to whether their traditional uses are supported by actual pharmacological effects or 
merely based on folklore (Mohamad et al., 2011; Rabe and van Staden, 1997). The 
medicinal plant Annona muricata has been reported to be effective when applied 
topically as well as internally, for insomnia, diabetes, abscesses, headaches (de 
Sousa et al., 2010) while Artemisia afra has been employed in treating ailments 
ranging from coughs to kidney disorders (Liu et al., 2009).  
 
Bioassays for detecting activity against M. tuberculosis include: Microplate Alamar 
Blue assay (MABA), ρ-iodonitrotetrazolium chloride (INT) assay and flow cytomtery. 
MABA is a colorimetric method using an oxidation/reduction indicator dye, alamar blue 
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that changes colour from blue to pink to indicate bacterial growth and can be read 
visually without the need for instrumentation (Collins and Franzblau, 1997). The ρ-
iodonitrotetrazolium chloride (INT) assay is similar to MABA, however it uses p-
Iodonitrotetrazolium chloride (INT) dye which acts as an electron acceptor and is 
reduced to a purple/pink colour by biologically active organisms.  
 
The flow cytometry method employing fluorescein diacetate (FDA) is based on the 
ability of mycobacteria to hydrolyse fluorescein diacetate (FDA) to free fluorescein via 
non-specific cellular esterases. Accumulation of fluorescein in metabolically active 
mycobacterial cells can then be easily detected by using a flow cytometer. By contrast, 
mycobacteria that are killed or inhibited by anti-mycobacterial agents hydrolyse 
significantly less FDA and therefore have reduced levels of fluorescence (Kirk et al., 
1998).  
 
Reports at the end of 2010 indicated that there was an estimated 34 million people 
currently living with HIV globally, 2.7 million new infections and 1.8 million deaths due 
to AIDS related illnesses worldwide (UNAIDS, 2011). South Africa remains the most 
severely affected country with the HIV/AIDS epidemic having almost half of the total 
AIDS related deaths in 2010 as well as an estimated 5.6 million people living with HIV, 
more than any other country in the world (UNAIDS, 2011). 
 
As a result, an appreciable amount of research efforts have been devoted to the 
discovery of improved anti-retroviral agents especially through the screening of natural 
products. Only 25 drugs for the treatment of AIDS have been approved to date, of 
which none are a natural product (Sabde et al., 2011). Due to their relatively low cost, 
plants have been increasingly explored for production of medicinal compounds and 
vaccines. Many plant derived substances including phenyl coumarins and plant 
proteins have shown good anti-HIV activity (Tshikalange et al., 2008).  
 
Some of the main targets for HIV treatment include specific enzymes which are vitally 
important in the HIV life cycle such as reverse transcriptase, integrase and protease 
enzymes. HIV-1 reverse transcriptase is a multifunctional enzyme which catalyzes the 
synthesis of proviral DNA, using viral RNA as a template (Menéndez-Arias, 2002). 
HIV-1 integrase is responsible for two of the most essential steps in the HIV life cycle, 
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3’-processing and DNA strand transfer (Craigie, 2001). Due to the fact that HIV 
integrase plays such an integral role in the replication of HIV and because no cellular 
homologues are found in humans, inhibitors targeted selectively at HIV integrase are 
expected to have low cytotoxicity (Xu et al., 2009). HIV-1 protease functions by 
cleaving a number of specific sites on the precursor gag and pol polyproteins thus 
releasing other viral proteins. It is therefore essential for the production of infectious 
viral particles because if these polyproteins are not cleaved, no infectious viral 
particles are produced (Weber et al., 2001). For that reason, HIV protease is a prime 
target for anti-viral agents but because of the rapid development of inhibitor resistant 
variants of the protease enzyme, the therapeutic effectiveness of potential inhibitors is 
limited (Weber et al., 2001).   
 
HIV-1 reverse transcriptase inhibition is detected using a non-radioactive colorimetric 
enzyme immunoassay, which determines the quantity of retroviral reverse trancriptase 
activity by incorporation of digoxigenin and biotin labelled dUTP into DNA, producing a 
coloured reaction product. HIV-1 integrase is also detected using a colorimetric 
enzyme immunoassay, which quantitatively measures the inhibition of HIV-1 strand 
transfer activity due to the presence of interacting agents. 
 
The objective of this chapter was to investigate two South African medicinal plants: A. 
muricata and A. afra for potential anti-TB activity by preliminary bioassay screening 
using MABA, INT assays and flow cytometry. In addition the inhibition of important HIV 
enzymes in the virus lifecycle i.e. reverse transcriptase and integrase were also 
determined. The selection of plants for evaluation was based on traditional use and 
the presence of highly active compounds like acetogenins and terpenes, which have 
previously been shown to possess anti-TB and anti-HIV activity (Cantrell et al., 2001; 
Vik et al., 2007 and Sun et al., 2003). 
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3.2 RESULTS 
 
3.2.1 Anti-TB Screening 
3.2.1.1 Microplate Alamar Blue Assay 
 
The Microplate Alamar Blue Assay using M. tuberculosis H37Rv ATCC 27294 (7 tests) 
revealed that the ethanolic extract of A. muricata produced ˃81% inhibition of M. 
tuberculosis at an MIC of 125 μg/mL. From visual observation, MIC values of five 
control drugs were 0.3125 µg/mL (rifampicin), 2 µg/mL (ofloxacin), 0.4 µg/mL 
(isoniazid), 15 µg/mL (ethambutol) and 2 µg/mL streptomycin (Fig. 3.1). Percentage 
inhibition of M. tuberculosis calculated from MABA absorbance values was, 75.89% 
(rifampicin), 91.09% (ofloxacin), 91.04% (isoniazid), 92.13% (ethambutol), 91.76% 
(streptomycin), and 81.63% for A. muricata (Fig. 3.2, Appendix Table A1). A. afra 
(aqueous and ethanolic extract) did not show any anti-TB activity using MABA at the 
highest concentration tested. 
 
 
 
 
 
Figure 3.1: Anti-TB activity of A. muricata using MABA. Well 2 (all rows): Antibiotic Control. Well 11 
(all rows): Bacterial Growth Control. Concentrations of antibiotics: Rifampicin wells 3-10 
(0.016 – 2.0 μg/mL), Ofloxacin wells 3-10 (0.031 – 4.0 μg/mL), Isoniazid wells 3-10 
(0.003 – 0.4 μg/mL), Ethambutol wells 3-10 (0.117 – 15.0 μg/mL), Streptomycin wells 
3-10 (0.016 – 2.0 μg/mL). Concentrations of A. muricata wells 3-10 (3.906 – 500 
μg/mL).  
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Figure 3.2: Percentage inhibition of M. tuberculosis determined using MABA for the five control 
drugs and for A. muricata. Data points represent the mean ± SD of several 
determinations, representative of seven independent experiments. 
 
3.2.1.2 ρ-Iodonitrotetrazolium Chloride Assay 
 
The ρ-iodonitrotetrazolium chloride assay using M. tuberculosis H37Rv ATCC 27294 
(7 tests) indicated that the ethanolic extract of A. muricata showed inhibition of M. 
tuberculosis with MIC 125 μg/mL which corresponds to the MIC obtained by MABA 
(Fig. 3.3). A. afra (aqueous and ethanolic extract) did not show any anti-TB activity 
using INT assay, which confirmed the results obtained using MABA. 
 
 
 
Figure 3.3: Anti-TB activity of A. muricata using INT assay. Well 11 (all rows): Bacterial Growth 
Control. Wells B-G: replicates of Annona muricata.  Concentrations of Annona 
muricata: wells 2 – 10: 500 μg/mL - 3.906 μg/mL. 
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Figure 3.4: Percentage inhibition of M. tuberculosis determined using INT for the five control drugs 
and for A. muricata. Data points represent the mean ± SD of several determinations, 
representative of seven independent experiments. 
 
 
3.2.1.3 Flow Cytometry  
 
Susceptibility of Mycobacterium tuberculosis H37Rv ATCC 27294 was determined by 
comparing the mean channel fluorescence of the drug free control with those that 
were exposed to antibiotics and plant extracts. For the seven tests, there was a 
decrease in the mean channel fluorescence of the antibiotic treated samples, at 
various concentrations, compared to the drug free control, indicating susceptibility of 
M. tuberculosis cells after exposure to ethambutol, which resulted in 74.1% inhibition 
(Figure 3.5A). A similar effect was observed for the M. tuberculosis and extract treated 
samples compared to the extract free control (Figure 3.5B), with the ethanolic extract 
of A. muricata producing 57% inhibition at a concentration of 500 µg/mL. Of the five 
control drugs previously used for MABA and INT, only ethambutol was used for flow 
cytometry because of discrepancies when the other antibiotics were used. Due to 
negative inhibitory results obtained for both the aqueous and ethanol extracts of A. 
afra in both the MABA and INT assays, they were not tested utilising flow cytometry 
due to the financial implications of the technique. 
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Figure 3.5: Flow cytometry data of the M. tuberculosis culture H37Rv ATCC 27294 exposed to 
various concentrations of (A) ethambutol (B) Annona muricata versus the untreated 
growth control.  Percentage inhibition was calculated using the mean fluorescence 
intensities of metabolised FDA. Data points represent the mean ± SD of several 
determinations, representative of seven independent experiments. 
 
3.2.1.4 Comparison of bioassays used for detection of anti-TB activity of A. 
muricata 
 
Comparison of bioassays revealed that MABA exhibited 100% sensitivity and is 
considered to be the best assay when compared with INT and flow cytometry, which 
exhibited sensitivities of 85.7% and 100% respectively (Table 3.1). However, only one 
antibiotic was used for flow cytometry and therefore the 100% sensitivity is not directly 
comparable to the other methods utilised. There was a strong correlation between 
MABA and INT as both assays indicated an MIC of 125 μg/mL. However, flow 
cytometry is a more sensitive technique and detected small amounts of inhibition 
occurring at low concentrations of antibiotic and extract and therefore the MIC was 
inconclusive. 
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Table 3.1: Comparison of the assays used for detection of anti-tuberculosis activity.  
 
  M. tuberculosis H37Rv ATCC 27294      
 
Antibiotics (A) Plant Extracts (P) 
Total Tests 
for 
antibiotics 
Total 
Tests 
for 
plant 
extracts 
Sensitivity 
(%) 
Assay 
Reproducible 
Results 
Discrepancies 
Reproducible 
Results 
Discrepancies 
   
A
 
P
 
MABA 7 0 7 0 7 7 100 100 
INT 6 1 6 1 7 7 85.7 85.7 
Flow 
Cytometry 
7 0 7 0 7
a 
7 100 100 
   *Sensitivity = [(no. True positives)/(no. True positives + no. False negatives)] * 100 
   
a
Only one antibiotic was utilised – Ethambutol, as discrepancies occurred with other antibiotics 
 
    
Direct comparison of the results obtained with the different methods revealed the 
following: MABA and flow cytometry produced statistically significant differences with 
regards to the average percentage inhibition obtained (P < 0.05). MABA and INT did 
not show statistically significant differences, indicating that they produced very similar 
average percent inhibitions, whereas INT and flow cytometry also produced 
statistically significant differences (Appendix Table A3). 
 
3.2.2 Anti-HIV Screening 
3.2.2.1 HIV-1 Reverse Transcriptase Assay 
The non-radioactive ELISA assay used to determine reverse transcriptase inhibition (3 
tests in triplicate) revealed that the only extract exhibiting significant reverse 
transcriptase inhibition was the aqueous extract of A. afra with ˃78% inhibition at 0.5 
mg/mL. The ethanolic extracts of A. muricata and A. afra showed no inhibitory activity 
against reverse transcriptase at very high concentrations of the extracts. Nevirapine, 
supplied by Aspen, was used as the positive control and exhibited 100% inhibition of 
reverse transcriptase at concentrations higher than 2 mg/mL (Fig. 3.6 and Fig. 3.7). 
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Figure 3.6: Visual representation of colour change observed for five concentrations (in triplicate) of 
the aqueous extract of Artemisia afra. A1, B1, C1: 0.2 mg/mL; D1, E1, F1: 0.5mg/mL; 
A2, B2, C2: 1 mg/mL; D2, E2, F2: 2 mg/mL; A3, B3, C3: 4 mg/mL; G1, G2, D3: 
Nevirapine (0.5 mg/mL); H1, H2, E3: Negative Control. 
 
Figure 3.7: Percentage inhibition of HIV-1 reverse transcriptase obtained for various concentrations 
of ethanolic extract of A. muricata and aqueous and ethanolic extracts of Artemisia afra. 
Positive control [Nevirapine (Aspen) – 2 mg/mL, 100% inhibition]. Data points represent 
the mean ± SD of three determinations, representative of three independent 
experiments. 
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3.2.2.2 HIV-1 Integrase Assay 
The non-radioactive enzyme immunoassay used to determine integrase inhibition (2 
tests in triplicate) indicated that all extracts possessed activity against HIV-1 integrase 
(Fig. 3.8). The ethanolic extracts of A. afra and A. muricata produced similar results, 
with extensive inhibition ˃86.8% and ˃88.54% respectively at concentrations >0.5 
mg/mL to 4 mg/mL. The aqueous extract of A. afra produced less activity, but still 
noticeable with inhibition of HIV-1 integrase ˃52.16% at 0.5 mg/mL increasing to 
72.89% at 4 mg/mL of the extract. It was possible to determine IC50 values for A. 
muricata, the ethanolic extract of A. afra and the aqueous extract of A.afra. They were 
0.125 mg/mL, 0.082 mg/mL and 0.450 mg/mL respectively.  
 
Figure 3.8: Percentage inhibition of HIV-1 integrase obtained for various concentrations of 
ethanolic extract of A. muricata and aqueous and ethanolic extracts of Artemisia afra. 
Data points represent the mean ± SD of three determinations, representative of three 
independent experiments. 
 
The positive control used for HIV-1 integrase inhibition was sodium azide at 
concentrations ranging from 0.25 to 2% (v/v) (Fig. 3.9).  Sodium azide, at 
concentrations 1% and above, achieved HIV-1 integrase inhibition ˃97%. 
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Figure 3.9: Percentage inhibition of HIV-1 integrase obtained for various concentrations of sodium 
azide (a known inhibitor of HIV-1 integrase). Data points represent the mean ± SD of 
three determinations, representative of three independent experiments. 
 
3.3 DISCUSSION 
 
The increase of resistance to conventional antibiotics by Mycobacterium tuberculosis 
has necessitated the search for new, efficient and cost effective ways for the control of 
this disease as well as a more rapid approach in novel drug discovery which would 
also aid in the control of MDR-TB (Green et al., 2010).  
 
A. muricata ethanolic extract exhibited anti-TB activity while A. afra showed no activity. 
In traditional medicine A. muricata extracts are used to alleviate coughs, asthma and 
chest pains and thus this anti-TB activity is relevant. It has also been known to be 
effective against Staphylococcus aureus, Enterococcus faecalis, Escherchia coli and 
Plasmodium falciparum (Yasunaka et al., 2005 and Boyom et al., 2011). This is the 
first report of an A. muricata extract showing activity against M. tuberculosis. 
 
Inhibitory activity of A. afra, has been reported against M. tuberculosis but only in 
certain chemical extracts. Ntutela et al. (2009) used aqueous, methanol and 
dichloromethane extracts of A. afra and showed, that only the dichloromethane extract 
inhibited M. aurum and M. tuberculosis cultures in a dose dependant manner, with the 
methanolic and aqueous extracts having no inhibitory effects. However, it was found 
that treatment of M. tuberculosis infected mice with the aqueous extract of A. afra 
regulated pulmonary inflammation during early infection (Ntutela et al., 2009 and Patil 
et al., 2011). These reports were confirmed by Liu et al. (2009) and Mativandlela et al. 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
0.25 0.5 1 1.5 2 
P
e
rc
e
n
ta
g
e
 I
n
h
ib
it
io
n
 o
f 
H
IV
-1
 I
n
te
g
ra
s
e
 
Concentration of Sodium Azide (%) 
44 
(2008) who also found no anti-TB activity present in the methanolic extract of A. afra, 
but when Mycobacterium smegmatis was tested, inhibitory activity was detected. This 
corresponds to our findings, with no activity in the ethanolic extract of A. afra. This lack 
of activity may be as a result of the solvents used as the different phytochemicals 
present in the plant extract into different solvents due to the differences in polarity. A. 
afra has a wide array of phytochemicals present ranging from monoterpenoids to 
sesquiterpenes (Liu et al., 2009). The solvent used to extract certain phytochemicals 
would differ, for example, some plants contain alkaloids that will only extract into 
alcohol, whereas others contain an alkaloid that will extract into water, but will be 
destroyed in alcohol. Therefore the most active phytochemicals may extract best into 
dichloromethane (Ntutela et al., 2009).  
 
The overall performance of MABA in this study was good indicating MIC’s of the 
antibiotics by visual detection. This is in agreement with reports of MABA for 
susceptibility testing demonstrated by other investigators, including a concordance 
rate of 93.6% with the BACTEC 460 results observed by Franzblau et al. (1998); 
Bastian et al. (2001); Chauca et al. (2007); Leonard et al. (2008); Estrada-Soto et al. 
(2009); Alba-Romero et al. (2011); Lawal et al. (2011) and Tekwu et al. (2012). The 
INT assay, which also performed adequately, exhibited identical results to that of 
MABA, showing anti-TB activity at MIC of 125 μg/mL for A. muricata.  INT also 
confirmed that no anti-TB activity was present in A. afra. The INT assay has been 
applied to E. coli, S. aureus, P. aeruginosa and M. smegmatis for the detection of 
antibacterial activity (Eloff, 1998; Kuete et al., 2008; Smith and McFeters, 1997). 
 
Due to the biohazard risk of M. tuberculosis, exposure to 10% formaldehyde for one 
hour was required in order to kill the TB cells. The addition of the formaldehyde 
decreased the colour intensity of the wells, consistently including the control. There 
was a strong correlation with the visual MIC’s and the fluorimetric readings obtained, 
which is similar to the findings of Collins and Franzblau (1997), who reported a high 
correlation between MIC obtained visually and fluorimetrically using MABA. MABA has 
many advantages by being a non-radiometric, inexpensive, rapid, high-throughput 
assay, which could prove very useful for large scale screening of plant extracts against 
M. tuberculosis.  
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Flow cytometry makes use of fluoroscein diacetate (FDA) for the detection of M. 
tuberculosis, FDA diffuses across cell walls and membranes by active transport and is 
rapidly hydrolyzed by mycobacterial esterases. Metabolically inactive cells have 
decreased quantities of esterases and thus exhibit less fluorescence. Mycobacteria 
are susceptible to various anti-mycobacterial agents and the effect of these on the 
cells causes decreased capacity to hydrolyze FDA. Susceptibility was determined by 
comparing the mean channel fluorescence of the drug free control with those that 
were exposed to the antibiotic, ethambutol, and the plant extract A. muricata. The 
decrease in mean channel fluorescence for those cells that were treated with 
ethambutol, were similar to findings  of Kirk et al. (1998); Reis et al. (2004) and 
Norden et al. (1995). The A. muricata exposed samples also exhibited a decrease in 
the mean channel fluorescence similar to the drug control. 
 
It was also possible to determine which assay was the cheapest and fastest to 
conduct, however when observing the price, there was no substantial difference 
between the preparation and starting materials of each assay, provided that the 
necessary equipment was already available. In terms of duration, MABA and INT took 
longer as they required 10 days growth period and 7 days assay incubation whilst flow 
cytometry only requires 3 days assay incubation in addition to the 10 day growth 
period. This 5 day difference favours flow cytometry with a shorter duration for 
obtaining results, however flow cytometry did not provide accurate MIC values and is 
more technically complicated to conduct as opposed to MABA and INT. 
 
MABA was the most sensitive and simplest with regards to antibiotic and plant extract 
testing, and was 100% reproducible for both. Flow cytometry can only be used for the 
detection of susceptibility of M. tuberculosis to antibiotics, as accurate MIC values 
could not be ascertained. INT showed 85.7% reproducibility, possibly because of the 
presence of chloride in the dye, which may have interfered with the results obtained. 
 
This is the first report of the plant extract A. muricata showing anti-TB activity. There is 
paucity of information and scientific validation on the use of plant extracts to cure 
tuberculosis and its related symptoms. Further experiments need to be conducted to 
confirm this finding and to determine the active compound of the A. muricata extract 
which is causing inhibition of M. tuberculosis. 
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Despite advances in anti-retroviral therapy which has transformed HIV/AIDS from a 
fatal to a manageable chronic disease, there remain considerable challenges. Highly 
active anti-retroviral therapy (HAART) is limited by its cost, the requirement of lifelong 
adherence, toxicity and side effects. In addition, the poor results of vaccine 
development along with the emergence of drug resistant HIV strains makes it 
impossible to rely on a few standard drug regimens (Leteane et al., 2012; Bessong et 
al., 2005; Klos et al., 2009; Mukhtar et al., 2008). 
 
The HIV enzymes, such as reverse transcriptase, integrase and protease, have been 
specific targets for many therapeutic drugs. The aqueous extract of A. afra exhibited 
substantial inhibition of HIV-1 reverse transcriptase while the ethanolic extracts of A. 
afra and A. muricata showed slight inhibition but at very high concentrations of the 
extracts. It was recently reported by Lubbe et al. (2012), that A. afra possesses anti-
HIV activity through the utilisation of tea infusions, however the method of detection 
was different to this study. Lubbe et al. (2012) made use of two independent 
approaches, namely the Infection format of Fusion Induced Gene Stimulation (iFIGS) 
and the dual enhancement of Cell Infection to Phenotype Resistance (deCIPhR), 
which both used genetically modified human HeLa cell lines, which were infected with 
HIV-1. However, inhibition of HIV-1 reverse transcriptase activity has not been 
previously documented for Artemisia afra aqueous extract. The anti-HIV activity 
reported by Lubbe et al. (2012) could possibly be a result of the reverse transcriptase 
inhibition observed in the present study. 
 
Liu et al. (2009) reported that the combination of A. afra with standard forms of HIV 
treatment yielded positive results and suggested that A. afra may exhibit some 
antiviral activity or immune boosting properties. The ethanolic extract of A. afra 
exhibited considerably lower activity when compared to the aqueous extract. This may 
be due to solvent compatibility to phytochemical extraction, the ethanol may destroy 
the active compound(s) responsible for the HIV reverse transcriptase inhibition. 
 
The ethanolic extracts of A. afra and A. muricata showed greater activity against HIV-1 
integrase than that of the aqueous extract of A. afra. This is interesting and suggests 
that there is a specific mechanism and a specific compound acting in each mode of 
inhibition and not just a compound which has a general affect on the envelope or the 
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receptors of the virus. The activity observed for the ethanolic extracts of A. afra and A. 
muricata was very similar, which might suggest that the ethanol extracted a compound 
which is structurally similar to both plants. The activity exhibited from A. muricata may 
be due to the group of compounds known as acetogenins, as they have previously 
displayed anti-HIV activities at very low concentrations (Aminimoghadamfarouj et al., 
2011). The inhibition of HIV-1 integrase by A. afra and A. muricata has not been 
previously documented. It would be beneficial to determine which phytochemical(s) 
are being produced from each of these plants, that are responsible for this activity 
against HIV-1 integrase and to establish whether the active chemicals are similar. 
 
The determination of anti-HIV-1 protease activity exhibited by these two extracts would 
have provided more evidence to the efficacy of these two extracts against HIV, 
however due the availability of reagents being limited and the cost for an appropriate 
kit being out of budget, anti-HIV-1 protease activity was unfortunately not determined. 
 
These findings provide evidence that natural sources, such as plants, can provide 
new, inexpensive means of treatment. However, further experiments should be 
conducted in order to verify the anti-HIV activities exhibited by A. muricata and A. afra 
as well as to identify the active compounds present. 
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CHAPTER FOUR 
 
PLANT EXTRACT CYTOTOXICITY AND SYNERGISTIC EFFECTS 
 
4.1 INTRODUCTION 
Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) have a very high 
prevalence in South Africa and it is known that the current treatment therapies used to 
combat TB and HIV can lead to adverse reactions such as hepatotoxicity. The 
incidence of hepatotoxicity may vary from 2 to 28% in different populations and can 
occur even when the drug has been given at the recommended doses (Tostmann et 
al., 2008; Singh et al., 2011). This side effect often results in patients discontinuing 
treatment, which inevitably leads to morbidity, mortality and most likely the emergence 
of drug resistant strains (Singh et al., 2011). 
 
As a result of this high hepatotoxicity, many individuals have redirected their interest to 
natural products such as plants. The secondary metabolites produced by some plants 
possess many biological activities, either serving as protective agents against various 
pathogens or as specific growth regulatory molecules, which can stimulate or inhibit 
cell division (Mativandlele, 2008). The popular perception is that, because the 
products from plants are natural, they are safe and that they have been used for 
centuries without harmful effects (Willet et al., 2004). The history of a product’s use is, 
however, not a guarantee of safety, particularly with respect to long term use, at 
relatively high doses or with other medications (Willet et al., 2004). One of the most 
serious safety concerns for natural plant product usage, is the potential for liver injury, 
as many have documented that herbal products such as kava, germander, chaparral, 
Ephedra, and comfrey have been associated with rare but severe cases of liver failure 
(Estes et al., 2003; Favreau et al., 2002; Stedman, 2002; Teschke et al., 2003; Willet 
et al., 2004). As a result of these reactions, the cytotoxic evaluation of plant extracts is 
essential before they can be considered for new drug development. 
 
Cytotoxicity tests are part of developing a potential pharmaceutical product into a 
clinically acceptable drug. These tests provide a screening method to determine that 
the compounds being tested are not more harmful to the normal biological processes 
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than the effects they are being tested for (Mativandlele, 2008). There are various 
methods to screen for possible cytotoxic effects of plant extracts, however the simplest 
and most commonly used is that of the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazolium bromide (MTT) assay. It provides a quantitative approach of determining 
mammalian cell survival and proliferation in vitro. There are many other methods such 
as the sulforhodamine B (SRB) assay and the chlonogenic assay. 
 
As a result of plant extracts being used as alternative medicine to alleviate the 
symptoms of TB and HIV, it is important to determine if any synergistic or antagonistic 
relationships could develop between the newly found plant extracts and existing drugs 
which the patient may be using. Synergism is defined as a positive interaction created 
when two agents are combined and together they exert an inhibitory effect on the 
targeted organisms that is greater than the sum of their individual effects (Chanda and 
Rakholiya, 2011). Antagonism occurs when the effect of two drugs together is less 
than the effect of either alone and indifference is when no effect is exhibited (Chanda 
and Rakholiya, 2011).  
 
Altered pharmacokinetics almost inevitably leads to a significant change in the 
response to drugs that have narrow therapeutic indices; however, given that a single 
herbal preparation may contain more than 100 components, all of which may have 
unknown biological activities, a herb has the potential to mimic, increase, or reduce 
the effects of co-administered drugs through simultaneous effects on the same drug 
targets (Zhou et al., 2007). If the effect of the drug in combination with the herbal 
medicine is enhanced, i.e. synergistic or additive effect, unfavourable toxicity may 
occur. By contrast, some herbal remedies may contain compounds with antagonistic 
properties, which are likely to reduce drug efficacy and produce therapeutic failure 
(Zhou et al., 2007). The synergistic or antagonistic effects between herbs and drugs 
often result from the competitive or complementary effect of the drug and the co-
administered herbal constituents at the same drug targets (Zhou et al., 2007).  
 
In phytotherapy, there are significant advantages that can be associated with 
synergistic interactions, such as increased efficiency, reduction of undesirable effects, 
increase in stability or bioavailability of the free agents and obtaining an adequate 
therapeutic effect with relatively small doses, when compared with synthetic 
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medication (Chanda and Rakholiya, 2011). Some examples where synergism has 
been observed include the experiments conducted by Souto de Oliveira et al. (2011) 
who showed synergistic activity of norfloxacin, tetracycline and erythromycin with the 
ethanol extract of Mangifera indica L. peel against S. aureus strains; Aiyegoro et al. 
(2009) showed that acetone, chloroform, ethyl acetate and methanol extracts of 
Helichrysum longifolium in combination with six antibiotics comprising of penicillin G 
sodium, amoxicillin, chloramphenicol, oxytetracycline, erythromycin and ciprofloxacin 
improved the bactericidal effects of the antibiotics against a panel of bacterial isolates; 
Chatterjee et al. (2009) showed the in vitro synergistic effect of doxycycline and 
ofloxacin in combination with ethanolic leaf extracts of Vangueria spinosa against four 
pathogenic bacteria. This substantiates the need for understanding the molecular 
mechanisms of synergy, which could provide a new strategy for the treatment of 
infectious diseases, overcome drug resistant pathogens and decrease the use of 
antibiotics and hence the side effects created by them. 
 
Therefore, the ethanolic and aqueous extracts of Artemisia afra and the ethanolic 
extract of Annona muricata were subjected to cytotoxicity testing with MTT and 
synergistic testing by the combination index method, performed using the Chang Liver 
cell line and the Human hepatoma cell line, HepG2. Previously it was shown that 
extracts with high antioxidant activity could convert the MTT dye to the purple 
formazan product, therefore it should be stated that the MTT assay was performed in 
such a way that the extracts did not interfere with the result, by firstly removing the 
extract before addition of the MTT, in fresh medium, and secondly the medium 
containing the MTT was removed after incubation and only the purple formazan 
crystals in the cells were solubilised with DMSO.  
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4.2 RESULTS 
 
4.2.1 Cytotoxicity 
 
4.2.1.1 Chang Liver Cell Line 
The cytotoxic effects of the aqueous and ethanolic extracts of A. afra and the ethanolic 
extract of A. muricata were determined using the MTT assay for Chang liver cells. The 
aqueous and ethanolic extracts of A. afra yielded IC50 values greater than 250 μg/mL 
and thus were considered to be nontoxic to confluent Chang liver cells (results not 
shown). The IC50 value obtained for the ethanolic extract of A. muricata against the 
confluent Chang liver cell line was 29.38 μg/mL (Fig. 4.1). From these results, the 
concentration of the ethanolic extract of A. muricata to be used for further experiments 
was fixed at 30 μg/mL for Chang liver cells.  
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Figure 4.1: Cytotoxic effect of A. muricata ethanol extract on confluent Chang liver cells after 24 
hours of exposure. Cell viability was determined by using MTT assay. Error bars 
indicate Standard deviation (SD) of ten replicate values. 
 
The cytotoxic effects for rifampicin, one of the first line drugs used to treat TB, was 
determined using the MTT assay for confluent Chang Liver cells. A concentration 
range between 0 and 150 µM was tested and the IC50 value obtained was 72.40 
μg/mL (Fig. 4.2). From these results, the concentration of rifampicin to be used for 
synergy experiments was fixed at 70 μg/mL for Chang liver cells. 
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Figure 4.2: Cytotoxic effect of Rifampicin on confluent Chang liver cells after 24 hours of exposure. 
Cell viability was determined by using MTT assay. Error bars indicate SD of four 
replicate values. 
 
4.2.1.2 HepG2 Cell Line 
The cytotoxic effects of the aqueous and ethanolic extracts of A. afra and the ethanolic 
extract of A. muricata were determined using the MTT assay for HepG2 cells. The 
aqueous and ethanolic extracts of A. afra yielded IC50 values greater than 250 μg/mL, 
similar to that of the Chang liver cells, and thus were considered to be nontoxic to 
confluent HepG2 cells (results not shown). The IC50 value obtained for the ethanolic 
extract of A. muricata against the HepG2 cell line was 76.68 μg/mL (Fig. 4.3). From 
these results, the concentration of the ethanolic extract of A. muricata to be used for 
further experiments was fixed at 77 μg/mL for HepG2 cells. 
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Figure 4.3: Cytotoxic effect of A. muricata ethanol extract on confluent HepG2 cells after 24 hours 
of exposure. Cell viability was determined by using MTT assay. Error bars indicate SD 
of four replicate values.  
53 
The cytotoxic effects for rifampicin were determined using the MTT assay for HepG2 
cells. A concentration range between 0 and 150 µM was tested and the IC50 value 
obtained was 134.80 μg/mL (Fig. 4.4). From these results, the concentration of 
rifampicin to be used for synergy experiments was fixed at 135 μg/mL for HepG2 cells. 
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Figure 4.4: Cytotoxic effect of Rifampicin on confluent HepG2 cells after 24 hours of exposure. Cell 
viability was determined by using MTT assay. Error bars indicate SD of four replicate 
values. 
 
4.2.2 Synergy Experiments using the CI method 
Combination studies were conducted using the IC50 values obtained in section 4.1, to 
determine whether there was a synergistic, antagonistic or purely additive effect when 
the ethanolic extract of A. muricata and the anti-TB drug, rifampicin, are used 
simultaneously. The combination index (CI) is the natural law based general 
expression of pharmacologic drug interactions (Chou, 2010). It is shown to be the 
simplest possible way for quantifying synergism or antagonism (Chou, 2010).  
 
Using the IC values, Ca and Cb values in Table 4.1, the combination index was 
determined using Equation below:  
 
    
  
                    
  
  
                
 
 
Example using the IC50 for A. muricata, rifampicin and the combination of both for 
Chang Liver cells:   
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The CI obtained in the example above was very close to 1, indicating a purely additive 
effect was achieved when the extract and rifampicin were used in combination. This 
equation was applied to all IC values obtained for both cell lines and CI results 
obtained are indicated in Table 4.1. 
 
Table 4.1: Summary of the IC25, IC50 and IC70 values obtained for the ethanolic extract, A. 
muricata alone, rifampicin alone as well as the IC25, IC50 and IC70 values of each when 
used in combination for both the Chang liver and HepG2 cell lines. Combination index 
also provided. 
 
 (A) Chang liver Cells (µg/mL) (B) HepG2 Cells (µg/mL) 
(a) Annona muricata   
IC25 9 ND 
IC50 30 77 
IC70 80 90 
   
(Ca) Combination IC25 5.322 ND 
(Ca) Combination IC50 22.43 27.78 
(Ca) Combination IC70 19.43 3.454 
   
(b) Rifampicin (A) Chang liver Cells (µM) (B) HepG2 Cells (µM) 
IC25 35 ND 
IC50 70 135 
IC70 47 145 
   
(Cb) Combination IC25 191.2 ND 
(Cb) Combination IC50 24.03 46.72 
(Cb) Combination IC70 26.04 5.819 
   
CI – IC25 6.05 ND 
CI – IC50 1.10 0.71 
CI – IC70 0.74 0.079 
*ND – Not determined 
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From Table 4.1, when focussing on Chang liver cells, it is evident that using A. 
muricata and rifampicin in combination only at their IC70 values produces a synergistic 
effect, where as an antagonistic effect is observed when used at their IC25 values and 
a purely additive effect when used at their IC50 values. For HepG2 cells, it seems that 
a synergistic effect is produced when the extract and rifampicin are used in 
combination at both the IC50 and IC70 values. This effect was more pronounced at the 
IC70.  No IC25 value was observed for HepG2 cells. 
 
4.3 DISCUSSION 
Cell based assays are frequently used for drug discovery using high throughput 
screening, environmental assessment of chemicals and biosensors for monitoring 
cellular behaviour (Vahdati-Mashhadian et al., 2007). Some biochemical methods, 
such as the MTT assay are widely used in toxicity screening assays. Due to the rapid 
spread of TB and HIV and the desperate need for novel, less toxic forms of treatment, 
natural products have become a major source of potential anti-TB and anti-HIV 
compounds. However, before these compounds can be considered for  human use, 
their cytotoxic properties need to be determined as well as any synergistic or 
antagonistic properties that might arise when used in combination with regular 
prescription drugs that are used for the treatment of TB and HIV. 
 
Chang liver and HepG2 cells were used for the cytotoxic experiments as they are both 
representative liver cell lines and as majority of drugs are detoxified by the liver, any 
cytotoxic effects produced from these extracts would thus have an effect on the course 
of TB and HIV treatment and thus would not be beneficial. Results of the MTT assay 
show that the ethanolic extract of A. muricata possesses significant toxicity at 
concentrations of 30 µg/mL and 77 µg/mL for Chang liver cells and HepG2 cells 
respectively. A. muricata has been reported to have cytotoxic effects on human 
melanoma cells, while the aqueous, ethanolic and pentane extracts had IC50 values 
greater than 500 µg/mL, 20 µg/mL and 120 µg/mL respectively (Menan et al., 2006). 
These cytotoxic concentrations produced by A. muricata are reasonably low, indicating 
that any dose greater than these concentrations will cause cell death, which is 
undesirable especially because A. muricata inhibited M. tuberculosis at an MIC of 125 
µg/mL. A. muricata posesses over 50 mono-THF acetogenins, which have been 
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proven to be cytotoxic against other cell lines such as U937’s, however further 
experiments need to be conducted in order to determine whether acetogenins are 
causing this cytotoxicity on Chang liver and HepG2 cells. 
 
The ethanolic and aqueous extracts of A. afra showed toxicity at concentrations 
greater than 250 µg/mL for both Chang liver and HepG2 cells. This finding is 
supported by Spies et al. (2013), who also reported an IC50 greater than 250 µg/mL. 
Spies et al. (2013) also reported the cytotoxic effects of the ethanolic and aqueous 
extracts of A. afra on HeLa and U937 cancer cell lines, with the aqueous extract 
showing no toxicity while the ethanolic extract had IC50 values of 31.88±1.09 μg/mL 
and 18.21±0.9 μg/mL against HeLa and U937 cells, respectively. The absence of 
cytotoxic effects from the ethanolic and aqueous extracts of A. afra on both the liver 
and hepatocyte cell lines is favourable as a dose of 0.2 mg/mL of the aqueous extract 
of A. afra causes ˃50% inhibition of HIV-1 reverse transcriptase, whereas a dose of 
0.075 mg/mL of the ethanolic extract of A. afra exhibits ≈50% inhibition of HIV-1 
integrase. 
 
Rifampicin is an important drug in the treatment of human mycobacterial and other 
infections. It is widely used as an essential drug in the treatment of tuberculosis and 
leprosy, in combination with other drugs (Vahdati-Mashhadian et al., 2007). The drug 
has been shown to produce hepatic toxicity in animal studies and tubulo-interstitial 
nephritis and acute renal failure is another adverse effect of the drug (Vahdati-
Mashhadian et al., 2007). The drug is also known to inhibit protein synthesis and 
induces chromosomal aberration (Vahdati-Mashhadian et al., 2007). In order to 
determine possible synergistic effects of these extracts, cytotoxicity of rifampicin on 
Chang liver and HepG2 cells was determined. Rifampicin yielded IC50 values of 57.7 
μg/mL (70 µM) and 111.1 μg/mL (135 µM) for Chang liver and HepG2 cells 
respectively. These results are similar to those presented by Vahdati-Mashhadian et 
al. 2007, where the toxic effect was evident from the concentration of 8.23 μg/mL (10 
μM) and increased in a concentration dependent manner. However, the maximum 
therapeutic plasma concentrations of rifampicin are 7-10 μg/mL, which overlaps the 
lowest toxic concentration in those experiments. IC50 values vary between experiments 
possibly due to the culture conditions or due to experimental procedure. Rifampicin 
was the only drug tested because the concentrations of nevirapine, ofloxacin, 
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streptomycin and ethambutol were too high in order to obtain cell death and required a 
high quantity of DMSO to dissolve. 
 
Using the IC25, IC50 and IC70 values for the ethanolic extract of A. muricata on the 
different cell lines and the IC25, IC50 and IC70 values obtained for rifampicin, synergistic 
and antagonistic effects could be determined. A. muricata was the only extract tested 
for synergistic effects, as it was found to be the only extract that possessed 
cytotoxicity, however the possibility of synergistic effects of the ethanolic and aqueous 
extracts of A. afra should not be disregarded. Using the combination index (CI) 
method of Chou-Talalay, as proposed by Chou, (2010), it was found that the CI for 
IC25 was 6.05 for Chang liver cells, which indicates a possible antagonistic effect when 
using rifampicin and A. muricata in combination, which could prove desirable in terms 
of toxicity as it may be possible that the extract could protect the patient from the toxic 
side effects of the drug. The IC25 for HepG2 cells was not determined. The CI for IC50 
was 1.10 and 0.71 for Chang liver and HepG2 cells respectively, which indicates a 
purely additive effect on Chang liver cells and a synergistic effect on HepG2 cells. The 
synergistic effect observed indicates that the extract could possibly enhance the toxic 
side effects of the drug, which could prove harmful to the patient, however these 
results are not an indication of the therapeutic effects that may occur.  The purely 
additive effect observed could even prove to be harmful because the patient’s liver 
could be challenged with the toxicity of the drug as well as that of the extract. The CI 
for IC70 was 0.74 and 0.079 for Chang liver and HepG2 cells respectively, which 
indicates a possible synergistic effect for both cell lines. 
 
When analysing these results, it looks promising that natural products can definitely 
play a major role in the search for novel drugs to fight TB and HIV. The ethanolic 
extract of A. muricata does prove to be cytotoxic and under certain conditions could be 
synergistic when used with rifampicin, however further testing needs to be conducted 
as there is no evidence as to what the extract is subject to in vivo and what changes 
may occur, which could lead to a less cytotoxic compound or an inactive compound all 
together. The same applies to the ethanolic and aqueous extracts of A. afra. It would 
also be beneficial to test the new found synergistic and antagonistic values on the 
actual microorganisms of M. tuberculosis and HIV in order to verify these results and 
determine whether or not the therapeutic effect will be enhanced or antagonised by 
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the combination of the extract and the drug. Isolation of the active compound is also 
important to ascertain whether the same compound is responsible for anti TB or anti-
HIV activities, cytotoxicity and synergy. 
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CHAPTER FIVE 
 
INTERACTIONS OF PLANT EXTRACTS WITH DRUG METABOLIC 
PATHWAYS 
 
5.1 INTRODUCTION 
There are more than 11 000 species of herbal plants that are used medicinally 
worldwide, most of which are often co-administered with therapeutic drugs raising the 
potential for drug herb interactions (Zhou et al., 2007). The use of medicinal plants 
against a variety of diseases is gaining popularity because of several advantages such 
as fewer side effects, better patient compliance, relatively low cost and high 
accessibility (Brown et al., 2008). Traditional herbal medicines that were formed and 
used thousands of years ago are still widely used today, especially in developing 
countries, where there is an abundance of indigenous knowledge (Brown et al., 2008).  
 
HIV/AIDS patients who make use of traditional herbal medicines may also 
simultaneously take prescription drug therapies, provided by clinics and hospitals, 
which could potentially cause drug herbal pharmacokinetic and/or pharmacodynamic 
interactions, depending on whether the drug has a narrow therapeutic index (Brown et 
al., 2008). Although the high risks associated with potential drug interactions is well 
known, 14–31% of prescription drug users combine herbal products with traditional 
medicines (Calalto et al., 2010). Due to this increased popularity and growth in sales 
of herbal medicinal products over recent years, many researchers have turned their 
focus to the pharmacological mechanisms underlying herb drug interactions (Calalto et 
al., 2010).  
 
Since the components of herbal products consumed must also be eliminated from the 
body by the same mechanism that removes drugs, there is a potential for interaction 
between herbal components and drugs (Ventkataramanan et al., 2006). Chemical 
constituents in herbal products, similar to prescription drugs, are eliminated by various 
metabolic enzymes in the body and may be substrates for various transporters. 
Possible herb drug interactions may alter drug bioavailability through altered 
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absorption, metabolism and distribution. Primary mechanisms of drug herb 
interactions involve either induction or inhibition of intestinal drug efflux pumps, such 
as P-glycoprotein (P-gp) and multiple resistance proteins (MRPs) as well as intestinal 
and hepatic metabolism by cytochrome P450s (CYPs) (Ventkataramanan et al., 2006). 
Many drug substances along with a variety of naturally occurring dietary or herbal 
components are capable of interacting with the CYP enzyme system and P-gp efflux 
pump in several ways:  
 
1. A herbal component can be a substrate of one or several isoforms of CYP enzymes 
and/or efflux systems. Therefore, one substrate can compete with another substrate 
for either metabolism by the same CYP isozyme and/or efflux system resulting in 
higher plasma concentrations due to competitive inhibition (Ventkataramanan et al., 
2006).  
 
2. A herbal constituent can also be an inducer of one or several CYP isoforms and/or 
efflux systems, thereby lowering plasma concentrations due to either higher 
metabolism and/or higher efflux. Such interactions may produce sub-therapeutic 
plasma drug concentrations (Ventkataramanan et al., 2006).  
 
3. A compound can also be an inhibitor of CYP450 enzymes resulting in reduced 
activity of one or several isoforms of CYPs. If a compound is an inhibitor of efflux 
system, it will reduce drug efflux resulting in improved absorption (Ventkataramanan et 
al., 2006).  
 
Absorption is a complex phase in pharmacokinetics and is a major determinant in drug 
efficacy and treatment outcome. The herbal interactions affecting it need to be 
considered, particularly in the case of drugs that have a narrow therapeutic index, 
such as digoxin or anti-cancer agents (Calalto, 2010). Given the increasing number of 
patients receiving multiple therapies, the FDA and European Medicines Agency (EMA) 
have recommended that pharmaceutical companies develop drug interaction 
investigations using cytochrome P450 and transporter enzymes because identifying 
possible factors and mechanisms involved with interactions related to drug absorption 
early in the development process helps to eliminate molecules with unwanted 
metabolic properties and guides medicinal chemists to produce better clinical 
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candidates and will inevitably aid the drug discovery process (Calalto, 2010). One 
major obstacle of drug absorption is intestinal metabolism. The cytochrome P450 
superfamily of enzymes on enterocytes metabolise, detoxify and bioactivate 
xenobiotics (Calalto, 2010). The most studied and abundant cytochrome is CYP3A4, 
which is located on the top of mature enterocytes and metabolises many drugs, 
(Calalto, 2010). 
 
Cytochrome activity can be drug modulated or change as a result of various 
polymorphisms. Some xenobiotics can enhance or reduce metabolism by inducing or 
inhibiting CYP activity, respectively, thereby increasing the range of variability up to 
400 fold (Calalto, 2010). Induction of these metabolic enzymes by xenobiotics 
decreases the amount of drug absorbed, leading to loss of clinical efficacy. On the 
other hand, inhibition of intestinal metabolism raises the amount of drug available 
increasing the possibility of toxicity and adverse drug reactions (Calalto, 2010). The 
P450 hydrophilic conversion of xenobiotics is followed by the chemical attachment of 
endogenous molecules, such as glucuronide, glycine, glutamine and glutathione; 
these secondary processes are mediated by phase II conjugating enzymes such as 
Glutathione-S-transferases (GST’s) and Sulfotransferases (SULT’s) (Calalto, 2010). 
 
GST’s are thought to play a physiological role in initiating the detoxification of potential 
alkylating agents including pharmacologically active compounds. These enzymes 
catalyze the reaction of such compounds with the -SH group of glutathione, thereby 
neutralizing their electrophilic sites and rendering the products more water soluble 
(Habig et al., 1974). Glutathione conjugates are thought to be metabolized further by 
cleavage of the glutamate and glycine residues, followed by acetylation of the 
resultant free amino group of the cysteinyl residue, to produce the final product, a 
mercapturic acid. The mercapturic acids are then easily excreted (Habig et al., 1974). 
 
Sulfotransferase enzymes catalyze the conjugation of sulfate groups onto a variety of 
xenobiotic and endogenous substrates that possess acceptor regions such as 
hydroxyl and amine groups (Chapman et al., 2002). The cofactor 3’-
phosphoadenosine 5’-phosphosulfate (PAPS) is required for sulfonation by these 
enzymes. Although sulfonation generally causes molecules to lose their biological 
activity, several documented examples indicate that the addition of sulfate can lead to 
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the formation of highly reactive metabolic intermediates (Chapman et al., 2002). 
Several sulfotransferase enzymes with different biochemical properties have been 
characterized in animal and human tissue. Two general classes exist in tissue 
fractions: the cytosolic enzymes, which are considered important in drug metabolism; 
and the membrane bound enzymes, which are involved in the sulfonation of 
glycosaminoglycans and glycoproteins (Chapman et al., 2002). There are currently 10 
known sulfotransferases in humans, five of which are known to be expressed in adult 
liver, namely SULT1A1, SULT1A2, SULT1A3, SULT1E and SULT2A1 (Chapman et 
al., 2002). 
 
Because the use of complementary and alternative medicines, including herbal 
medicines, is common among individuals with HIV, the possible herb drug interactions 
that may occur are relevant to this study. The use of herbal remedies complementary 
to antiretroviral (ARV) medicine may cause clinically significant interactions, especially 
because two important groups of ARVs, namely the non-nucleoside reverse 
transcriptase inhibitors and protease inhibitors are CYP substrates and have a small 
therapeutic range (Mills et al., 2005). It is expected that in Africa, where almost 80% of 
the inhabitants use traditional medicine and where the access to antiretroviral agents 
is growing, the risk for herb ARV interactions is higher (Snyman et al., 2005).   
 
Both protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), are mainly metabolized by CYP3A4 and, to a lesser extent, CYP2B6, 2C9, 
2C19, and 2D6 (van den Bout-van den Beukel et al., 2006). Multiple studies showed 
the existence of a number of important interaction risks of herbal medicines with 
antiretroviral agents and because many HIV patients use herbal medication in 
combination with antiretroviral therapy worldwide, more awareness and further 
research on the possible side effects and interactions that may occur are necessary 
(van den Bout-van den Beukel et al., 2006). 
 
Therefore it is of importance that potential drug herb interactions be identified in order 
to prevent adverse outcomes in patients taking combinations of drugs and herbal 
supplements (Ventkataramanan et al., 2006). Therefore, the ethanolic and aqueous 
extracts of Artemisia afra and the ethanolic extract of Annona muricata were analysed 
for Glutathione-S-Transferase inhibition as well as CYP3A4 inhibition. 
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5.2 RESULTS 
 
5.2.1 Detection of Glutathione-S-Transferase (GST) Interference 
Interruption of Glutathione-S-transferase activity was determined using the GST assay 
kit (Sigma), where the change in absorbance per minute of the extract treated GST 
samples was compared to an inhibitor and extract free control (Appendix Fig. A1). All 
experiments made use of 55 units/mg of GST, as this was found to be the optimum 
level of GST activity in order to observe a substantial interruption, if any occurred. All 
extracts were tested at 0.03125 mg/mL and 0.0625 mg/mL, because higher 
concentrations of the extracts interfered with the absorbance readings and produced 
inaccurate results. It was found, for the 0.0625 mg/mL test samples, that the ethanolic 
extract of A. muricata and the aqueous extract of A. afra had no significant effect on 
GST activity, with only 12.83% and 26.79% GST inhibition respectively. The ethanolic 
extract of A. afra however, was found to inhibit GST activity extensively, with 75.67% 
[Fig. 5.1 (B)]. When observing the tests conducted with the 0.03125 mg/mL 
concentration, the same trend was observed however with less GST disruption, where 
the ethanolic extract of A. muricata, the aqueous extract of A. afra and the ethanolic 
extract of A. afra yielded 11.16%, 19.21% and 61.44% inhibition respectively [Fig. 5.1 
(A)]. This concentration indicated that GST activity recovers in a dose dependant 
manner. 
 
Figure 5.1: Percentage inhibition of GST activity of the extract and inhibitor free control compared 
to the test samples where the various plant extracts are present. The concentration of 
the extracts used was (A) 0.03125 mg/mL and (B) 0.0625 mg/mL. Data points 
represent the mean ± SD of three determinations, representative of three independent 
experiments. 
(A) (B) 
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5.2.2 Detection of Cytochrome 3A4 (CYP3A4) Interference 
Susceptibility of CYP3A4 due to the presence of the ethanolic and aqueous extracts of 
A. afra and the ethanolic extract of A. muricata was determined by plotting the change 
in fluorescence per minute and determining the percentage inhibition obtained by the 
extract treated samples compared to an inhibitor and extract free control (Fig. 5.2). For 
the three tests conducted, it was found that all extracts exhibited CYP3A4 inhibition to 
some extent. The ethanolic extract of A. muricata had the highest range of CYP3A4 
inhibition, with 50% inhibition being achieved at 4.5 µg/mL and 97% inhibition being 
achieved at 500 µg/mL. The ethanolic extract of A. afra exhibited 50% inhibition of 
CYP3A4 at 25 µg/mL and 98% inhibition at 500 µg/mL. The aqueous extract of A. afra 
produced the lowest amount of CYP3A4 inhibition, however the inhibition was still 
noteworthy as 200 µg/mL exhibited 50% inhibition of CYP3A4 and 500 µg/mL 
exhibited 78% inhibition. 
 
 
Figure 5.2: Percentage inhibition of cytochrome 3A4 due to the presence of various concentrations 
of the ethanolic extract of A. muricata and the ethanolic and aqueous extracts of A. 
afra. Data points represent the mean ± SD of three determinations, representative of 
three independent experiments. 
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5.3 DISCUSSION 
It has been estimated that more than 80% of the Southern African population make 
use of traditional medicines, often in combination with prescription drugs and it is 
possible for the components of these medicinal plants to alter absorption and 
metabolism of conventional drugs leading to reduced efficacy of specific drug or 
systemic drug toxicity. Glutathione-S-transferases are thought to play a role in 
initiating detoxification of potential alkylating agents including pharmacologically active 
compounds (Habig et al., 1974). In the experiments where A. muricata and the 
aqueous extract of A. afra were present, the GST levels are reasonably similar to the 
GST control, therefore indicating that they have little effect on its activity. However, the 
ethanolic extract of A. afra, caused a drastic decrease of GST activity, indicating 
inhibition of GST activity by this extract. In all experiments, 55 units/mg of GST were 
used and the concentration of all extracts tested was 0.0625 mg/mL and 0.03125 
mg/mL, this was due to the fact that higher concentrations of the extracts interfered 
with the absorbance readings. 
 
Extracts of A. muricata and A. afra aqueous have little to no effect on GST indicating 
that their concurrent use with conventional medicines will have no effect on drug 
metabolism. This is favourable as these two extracts have shown activity against TB 
and HIV respectively (Chapter 3). The ethanolic extract of A. afra has a drastic effect 
on GST activity interfering with phase II metabolism by inhibiting glutathione 
conjugation. There is an extensive amount of phytochemicals present in A. afra and it 
is possible they are causing this disruption of GST, however further experiments need 
to be conducted to determine which compounds are responsible for this inhibition. 
The most important pathway for drug metabolism is the family of liver enzymes known 
as cytochrome P450, particularly 3A4, which is responsible for the metabolism of 
multiple drugs, including two important groups of ARVs, non-nucleoside reverse 
transcriptase inhibitors (NNRTI) and protease inhibitors (PI), which are also CYP 
substrates (Mills et al., 2005; Zhou et al., 2007; Patel et al., 2011). The activity of 
these enzymes may be induced or inhibited by the use of plant medicines (Patel et al., 
2011).  The consequences of inhibition of these CYPs by plant medicines would be 
higher antiretroviral plasma levels, thus putting patients at greater risk of serious side 
effects, whereas induction of CYP would lead to sub-therapeutic plasma levels, 
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leading to therapeutic failure and an enhanced risk of developing antiviral drug 
resistance (van den Bout-van den Beukel et al., 2006). 
 
These results indicate that all extracts, the ethanolic extract of A. muricata and the 
ethanolic and aqueous extracts of A. afra inhibit CYP3A4 activity in some way. The 
concentrations at which 50% of the enzyme was inhibited were 4.5 µg/mL, 25 µg/mL 
and 200 µg/mL respectively. These concentrations are extremely low when comparing 
them to effective dose concentrations that need to be used in order to treat TB or HIV. 
It is well known that A. muricata and A. afra possess many compounds that could 
bring about this CYP3A4 inhibition, such as certain sesquiterpenoids like 
chrysanthenyl acetate, several sesquiterpene lactones as well as non-volatile 
constituents like triterpenes, alkanes and flavonoids, and the highly active acetogenins 
like annonacin (Van Wyk, 2008; Aminimoghadamfarouj et al., 2011). However, the 
method and nature of CYP3A4 inhibition is unknown and further experiments need to 
be conducted to determine if the inhibition is due to substrate competition, substrate 
alteration or if the extracts change the surface of the actual CYP3A4 enzyme and 
affect binding in some way.   
 
These effects on GST and CYP3A4 are unfavourable due to the fact that therapeutic 
treatment will be affected in some way if these extracts are taken simultaneously with 
antiretroviral drugs and could in turn have a negative effect on the patient as opposed 
to the desired effect. However, it should be kept in mind that it is difficult to state that 
these will be the definite effects that will occur in the human body, as in vivo 
experiments may have a different outcome compared to in vitro experiments. It was 
suggested by Zhou et al. (2007) that a possible approach to overcoming unfavourable 
drug interactions with herbal remedies is to design new drugs that are so called ‘hard 
drugs’ which are not metabolized by CYPs and/or not transported by P-glycoprotein. 
These drugs cannot be metabolised and are excreted through either the bile or kidney 
with simple kinetics (Zhou et al., 2007). Thus, their pharmacokinetics will be simplified 
and usually predictable. When these drugs are administered, the potential for 
interactions with combined herbal remedies will be greatly reduced (Zhou et al., 2007). 
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CHAPTER SIX 
 
CONCLUSIONS 
 
6.1 THE RESEARCH IN PERSPECTIVE 
As a result of the increase in the spread of multidrug and extensively drug resistant 
strains of TB and the ineffectiveness of the current treatment against TB and HIV, the 
implementation of novel treatments is necessary. Due to the rich traditional values that 
Africa possesses, especially with respect to their traditional medicine and knowledge, 
many natural compounds can be identified and used to treat diseases like TB and 
HIV. The speed and accuracy of the method used to identify infection is important. At 
the start of this project, the effectiveness of two plant extracts, namely Annona 
muricata and Artemisia afra against TB and HIV was not known, and due to claims 
from traditional medicine reports which indicate effectiveness of these two plants 
against chest infections, coughing and certain antiviral properties, their potential 
activity against TB and HIV was investigated.  
 
Minimal information regarding methods for anti-TB detection have been suggested, 
thus this study set out to compare the effectiveness and sensitivity of three in vitro 
assays, namely MABA, INT and flow cytometry, for the detection of anti-TB activity of 
the plant extracts. MABA was the most sensitive and simplest assay with regards to 
plant extract testing, and was reproducible, followed by INT and flow cytometry. This is 
plausible based on the fact that MABA has been used specifically for M. tuberculosis 
testing previously whereas INT and flow cytometry have not. The results indicated 
anti-TB activity of the A. muricata ethanolic extract while both extracts of A. afra 
showed no activity. This is the first report of an A. muricata extract showing activity 
against M. tuberculosis. 
 
Due to the co-infection of many HIV infected patients with TB, it was appropriate to 
investigate whether the extracts that possessed anti-TB activity also had an effect on 
certain HIV-1 enzymes. Many publications, such as Bedoya et al., 2001; Bessong and 
Obi, 2006; Lamorde et al., 2010 and Lubbe et al., 2012 explain the effect of many 
plant extracts on HIV however the majority only focus on general HIV inhibition and 
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not on target HIV enzyme inhibition. The extract of A. muricata, which was the extract 
which possessed the highest anti-TB activity, had the least effect on HIV-1 reverse 
transcriptase but was the second most effective against HIV-1 integrase. This provides 
evidence that using this extract could possibly target HIV and TB simultaneously in 
one patient. A. afra extracts retained the highest activity against HIV, which 
unfortunately showed no activity against M. tuberculosis and thus may not combat 
both diseases however there is no interpretation of what may occur whilst the extract 
is in vivo. 
 
The objective of chapter 4 was to determine if these extracts, which now possess anti-
TB and anti-HIV activity, if administered to patients, will have any toxic effect on 
confluent Chang liver and HepG2 cells, which represent the liver in the human body 
and would be responsible for the extract detoxification process as well as the 
identification of any synergistic, antagonistic or additive effects between the extract 
and current therapeutic drugs. The MTT assay that was performed allowed for dose 
response curves to be conducted and IC50 values determined. Substantial toxicity from 
the A. muricata extract on both cell lines were found, which is unfavourable due to its 
anti-TB activity, which indicated that the liver may become damaged if the extract is 
taken in high doses. The extracts of A. afra exhibited no toxicity on the respective cell 
lines, which indicates high levels of the extract may possibly be taken and should not 
have any negative effect on the liver, however it should be noted that there is no 
interpretation of what may occur in vivo in a human host. In terms of combination 
experiments, only the extract of A. muricata was examined, but the A. afra extracts 
should not be excluded and it is encouraged that they should also be tested to 
determine if any synergistic, antagonistic or additive effects may occur. The results 
revealed that the IC values at which the extracts and the antibiotics are used are very 
important as there was a large difference in the combination effect at the various IC 
values. Only the combination index for the IC25  for Chang liver cells yielded an 
antagonistic result, while the remaining yielded synergistic effects on both Chang liver 
and HepG2 cells. These synergistic effects are unfavourable and indicate that the 
extract may cause unwanted enhanced toxicity of the rifampicin, the specific drug in 
this case, whereas the antagonistic result proves positive for possibly protecting the 
patient in respect to the drug’s toxic side effects. This is an interesting finding which 
may impact on future in vitro and in vivo experiments. 
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The observation of synergistic effects that may take place between the extract and the 
therapeutic drugs, implied that it was plausible to investigate whether any drug 
interactions could occur, based on the major drug metabolizing enzymes, such as the 
CYP3A4 and GST enzymes. These drug interactions aid in understanding whether the 
extracts had an effect on the vital enzymes responsible for detoxifying therapeutic 
drugs and thus giving insight into whether the extracts may affect the course of drug 
metabolism in some way and thus the treatment of these diseases. Only the ethanolic 
extract of A. afra had a significant effect on GST, while the other extracts showed no 
major effect. Investigation of the most important enzymes involved in metabolizing the 
majority of drugs, CYP3A4, showed interference from all extracts. This implies that the 
extracts may affect the drug metabolizing pathway where CYP3A4 is dominant, which 
may impede treatment of patients. 
 
6.2 POTENTIAL FOR FUTURE DEVELPOMENT OF THE WORK 
As natural sources are becoming increasingly popular as sources of anti-TB and anti-
HIV agents, the need for determining whether they are safe and whether they can be 
used in conjunction with modern day therapeutic drugs also increases. There are 
various aspects in this project that can be reviewed and built on for future work. Anti-
TB research is fundamental in South Africa, thus it could be useful to compare other 
methods of detection with the methods mentioned in this project in order to provide a 
broader comparison with regards to the most sensitive, cheapest and effective method 
for determination of anti-TB activity. Due to the presence of anti-TB activity in the 
ethanolic extract of A. muricata it might be valuable to ascertain which compound is 
responsible for inhibition of M. tuberculosis and the mode of action, whether it might 
target the mycolic acids present in the cell wall or target specific enzymes or inhibit 
DNA or protein synthesis of M. tuberculosis. It may also be interesting to determine 
whether the compound identified in A. muricata has the same effect on different 
species of mycobacteria, such M. aurum, M. avium and M. smegmatis as well as on 
resistant strains such as multi drug resistant (MDR) and extensively drug resistant 
(XDR) M. tuberculosis. 
 
For the detection of anti-HIV activity, the focus was on the enzymes reverse 
transcriptase and integrase because they are involved in the process of replication of 
HIV, therefore inhibition of either or both enzymes would be beneficial. For the 
70 
detection of integrase inhibition, a larger range of concentrations were used for each 
extract when compared to the range used to detect reverse transcriptase inhibition. 
Lower concentrations of the various extracts, mainly the aqueous extract of A. afra 
should be used to determine at which concentration the inhibition of HIV-1 reverse 
transcriptase is halted. The inhibition of HIV-1 integrase by A. afra and A. muricata has 
not been previously documented. It would be beneficial to investigate which 
phytochemical(s) are being produced from each of these plants, that are responsible 
for this activity against HIV-1 integrase and to establish whether the active chemicals 
are similar. Testing these extracts on other enzymes which are active in the HIV-1 life 
cycle would also prove valuable, such as that of the protease enzyme and determine if 
phytochemicals are acting in the same manner with each different enzyme or if each 
mode of inhibition varies. 
 
The cytotoxicity testing was conducted on two different cell lines, Chang liver and 
HepG2 cells, therefore it would be valuable if the extracts were tested on other cell 
lines, such as the Vero and RAW cell lines, which are representative kidney cells and 
macrophage cells respectively. Testing the extracts on these particular cells could 
provide insight into whether they are toxic to the kidney cells, which could prove 
detrimental as some of the extract will be excreted through the urine, or toxic to the 
macrophage cells, which may aid anti-TB detection as the macrophage cells would 
lyse, exposing the latent TB cells and make them vulnerable to treatment. Different 
cell viability assays could be used, however MTT has been proven to be the easiest, 
effective and the most sensitive. The synergistic experiments were only conducted 
with rifampicin as this was the only drug that could be dissolved in a low concentration 
of DMSO and still have an IC50 value on both cell lines, thus testing other anti-TB and 
anti-HIV drugs would be beneficial to determine if these specific extracts have any 
combinational effect when used with those therapeutic drugs. It would also be 
interesting to test the new found synergistic and antagonistic values on the actual 
microorganisms of M. tuberculosis and HIV in order to verify these results and 
determine whether or not the therapeutic effect will be enhanced or antagonised by 
the combination of the extract and the drug. It would also be interesting to ascertain 
whether the same compound is responsible for inhibitory activity, cytotoxicity and 
synergistic effects.  
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With regards to drug interactions, there are many enzymes involved in phase one and 
phase two metabolism, such as sulfotransferases, Uridine diphosphate 
glucuronosyltransferases and P-glycoproteins, and other cytochrome P450’s. It would 
be valuable to understand all aspects of drug interactions that may occur with these 
extracts, as they play a vital role in establishing whether a novel drug is accepted for 
trials or not. It would be important to test the effect of these extracts on 
sulfotransferase activity especially because sulfotransferases have been implicated in 
numerous detoxification and bioactivation pathways, however, little is known regarding 
its endogenous function (Frame et al., 2000).  
 
It should be noted that although these studies look promising, the human system is 
complicated and it is difficult to ascertain whether observations made in vitro will be 
the same as in vivo, therefore in vivo studies would be necessary to conclude as to 
whether the extracts undergo some kind of change when entering the stomach, 
passing through the colon and inevitably whether they would have the same effect on 
the TB and HIV diseases in the human host. 
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 APPENDIX 
 
Table A1: Average absorbance values for the growth control and test samples with the 
corresponding percentage inhibition for each of the drugs tested and plant extract, A. 
muricata. 
 
Antibiotic 
Growth Control 
Average (nm) 
Test Average 
(nm) 
Percentage 
Inhibition  
Rifampicin 23398.86 5642.14 75.89 
Ofloxacin 25593.86 2148.14 91.61 
Isoniazid 25965.43 2325.29 91.04 
Ethambutol 24986.71 1966.00 92.13 
Streptomycin 23795.57 1960.14 91.76 
Plant - Annona muricata 23593.71 4334.29 81.63 
 
 
Table A2: Various concentrations of ethambutol and Annona muricata with the corresponding X 
– Mean Fluorescence and percentage inhibition values obtained for the antibiotic 
tested M. tuberculosis cells and for the extract treated cells. 
 
Concentration 
of Ethambutol 
(μg/mL) 
Ethambutol X - 
Mean 
Fluorescence 
Percentage 
Inhibition 
 Concentration 
of Annona 
muricata 
(μg/mL) 
Annona 
muricata X - 
Mean 
Fluorescence 
Percentage 
Inhibition 
0 23.9 0.00  0 23.1 0.00 
15 6.19 74.10  500 9.9 56.97 
7.5 7.72 67.70  250 13.1 42.91 
3.75 8.26 65.44  125 13.9 39.94 
1.875 8.32 65.19  62.5 15.5 32.69 
0.938 8.86 62.93  31.25 19.4 16.04 
0.469 11.6 51.46  
0.234 14.2 40.59  
0.117 15.7 34.31  
0.059 16.4 31.38  
 
 
 
 
 
 
 
 
 
 
 
 
 Table A3: Two way analysis of variance (ANOVA) followed by Tukey’s HSD test was applied for 
statistical analysis with the level of significance set at P < 0.05 was conducted 
utilising MABA, Flow Cytometry and INT results to determine if the results obtained 
are significantly different from one another. 
 
 
{1} {2} {3} {4} {5} {6} 
Assay M=92.12 M=81.03 M=71.49 M=84.51 M=87.28 M=84.82 
MABA Control {1} 
 
0.0004 0.0001 0.0229 0.3026 0.0321 
MABA Plant {2} 0.0004 
 
0.0024 0.6527 0.0924 0.5663 
Flow Cytometry Control {3} 0.0001 0.0024 
 
0.0001 0.0001 0.0001 
Flow Cytometry Plant {4} 0.0229 0.6527 0.0001 
 
0.8266 1.0000 
INT Control {5} 0.3026 0.0924 0.0001 0.8266 
 
0.8869 
INT Plant {6} 0.0321 0.5663 0.0001 1.0000 0.8869 
 *M = Mean 
 *Red indicates statistical significance at the 5% level (p<0.05) 
 
 
 
 
Figure A1: GST activity, expressed in change in absorbance per minute, with no extracts or 
inhibitor present compared to GST activity with the various plant extracts present. 
Data points represent the mean ± SD of three determinations, representative of three 
independent experiments. 
 
0.0000 
0.0100 
0.0200 
0.0300 
0.0400 
0.0500 
0.0600 
0.0700 
0.0800 
C
h
an
ge
 in
 A
b
so
rb
an
ce
/m
in
u
te
 
GST Levels 
GST - No extract 
GST with A. muricata 
GST with A. afra aqueous 
GST with A. afra ethanol 
 LIST OF CONFERENCE PRESENTATIONS 
 
 
Paper presentation 
 
Pruissen, MC, M. van de Venter and S. Govender. 2012. Inhibitory activities of 
Artemisia afra and Annona muricata against Mycobacterium tuberculosis and Human 
Immunodeficiency virus. Indigenous Plant Use Forum (IPUF), University of Limpopo, 
2nd – 5th July. (This presentation received 2nd best paper presentation by a young 
scientist). 
 
 
 
